Quest Diagnostics Incorporated (DGX)

USD207.35 -0.09 (-0.04%)

US NYSE S&P 500 Healthcare Medical - Diagnostics & Research

Address 500 Plaza Drive 7094
Secaucus, NJ, US

CEO James E. Davis

Website questdiagnostics.com

IPO 1996-12-17

CIK 1022079 ISIN US74834L1008

Explore sections of this company profile

Section

Also trades on London Stock Exchange · 0KSX.L (USD) New York Stock Exchange · DGX (USD)

Description

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.

News Sentiment (7d)

Based on only 2 articles — low confidence

Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI PRNewsWire
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term Zacks Investment Research

Market Cap & Enterprise Value

Merger & Acquisition History

Target company	Ticker	Date	Filing
Unilab	ULAB	2002-05-15	View

Index membership

Index	Added	Removed	Status
S&P 500	2002-12-11	—	Active

Technical Outlook

Loading outlook…

Loading forecast...

Signal Summary Loading…

Indicator	1D	1W	2W	3W	1M

Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.

Day Score & sub-scores

Statistical fingerprint & regime detail

Conditional historical analysis

Customize analysis (advanced)

From To

Indicative levels generated algorithmically. Not financial advice.

Risk Profile

Loading risk profile…

Price Chart

From To

Averages

Trend

Price

Levels

Draw

USD207.35 -0.09 (-0.04%)

Loading historical data…

Volume Profile

From To

Loading…

Liquidity & share structure

Average Volume

928.0K

Beta

0.57

Float Shares

110.15M

Free Float %

99.5%

Price Performance

1D	5D	1M	3M	6M	YTD	1Y	3Y	5Y	10Y	Max
-0.66%	+0.33%	+0.36%	-8.03%	+3.02%	+12.31%	+12.44%	+45.58%	+53.14%	+152.56%	+5,468.57%

Rolling Volatility

Loading…

Drawdown

Loading…

Relative Strength

Loading…

Monthly Returns Heatmap

From To

Loading…

Annual Monthly Returns

Loading…

Daily Returns Distribution

From To

vs.

Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Compare

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (34 ratings, all time) Hold

Price Targets & DCF

Current price

207.35

Low 210.00 +1.3%

Consensus 220.57 +6.4%

Median 220.00 +6.1%

High 235.00 +13.3%

DCF (Unlevered) 227.73 +9.8%

DCF (Levered) 231.85 +11.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 50% Bullish

Rating	2026-05	Change
Strong Buy	2	0
Buy	7	0
Hold	9	0
Sell	0	0
Strong Sell	0	0

Price Target Summary

Period	# Analysts	Avg Target
Last Month	—	—
Last Quarter	3	220.00 +6.1%
Last Year	23	207.83 +0.2%
All Time	47	185.96 -10.3%

Quality scores

Altman Z-Score

3.33

Safe zone

Piotroski F-Score

7 / 9

Strong

MOAT Score

6 / 10

Developing

Composite Rating

B+

Overall Score

3 / 5

Medium

DCF Score

4 / 5

High

ROE Score

4 / 5

High

ROA Score

5 / 5

High

D/E Score

1 / 5

Low

P/E Score

2 / 5

Medium

P/Book Score

2 / 5

Medium

Operational MOAT

✗ Below peers

✓
Revenue growth Medical - Diagnostics & Research: +7.9%

+11.8% ★ Q1'26: +9.2% (vs Q1'25)
✓
EPS growth Medical - Diagnostics & Research: +30.8%

+13.8% Q1'26: +15.5% (vs Q1'25)
✓
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%

+10.3% ★ Q1'26: +5.7% (vs Q1'25)
✗
EBIT margin Medical - Diagnostics & Research: +9.6%

+14.7% ★ Q1'26: +13.8% (vs Q1'25)
✗
ROIC Medical - Diagnostics & Research: +5.2%

+9.1% ★ Q1'26: +8.7% (vs Q1'25)
✓
Share dilution Medical - Diagnostics & Research: 0.0%

+0.0% ★ Q1'26: -0.9% (vs Q1'25)
✗
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×

3.15× Q1'26: 4.00× (vs Q1'25)

Valuation Multiples From To

Price Forecast (3Y) From To

Model

Adjust

P/E

Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)

Projection years:

Market assumptions

WACC (%)

Terminal g (%)

▶ WACC components (optional)

Risk-free rate (%)

Market risk premium (%)

Ke (Cost of Equity) = Rf + β (0.60) × ERP

WACC = 76% × Ke + 24% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions

Revenue growth (%)

EBIT margin (%)

CapEx / Revenue (%)

Tax rate (%)

—

Intrinsic value (base): 227.73 Current price: 207.35

Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates

Metric	Dec 2001 actual	Dec 2002 actual	Dec 2003 actual	Dec 2004 actual	Dec 2005 actual	Dec 2006 actual	Dec 2007 actual	Dec 2008 actual	Dec 2009 actual	Dec 2010 actual	Dec 2011 actual	Dec 2012 actual	Dec 2013 actual	Dec 2014 actual	Dec 2015 actual	Dec 2016 actual	Dec 2017 actual	Dec 2018 actual	Dec 2019 actual	Dec 2020 actual	Dec 2021 actual	Dec 2022 actual	Dec 2023 actual	Dec 2024 actual	Dec 2025 actual	Dec 2026 13 Rev. Ana. 12 EPS Ana.	Dec 2027 14 Rev. Ana. 12 EPS Ana.	Dec 2028 11 Rev. Ana. 7 EPS Ana.	Dec 2029 5 Rev. Ana. 2 EPS Ana.	Dec 2030 5 Rev. Ana. 5 EPS Ana.
Revenue	3.63B est: 3.27B (+10.9%)	4.11B est: 3.83B (+7.4%)	4.74B est: 4.57B (+3.6%)	5.13B est: 5.08B (+0.9%)	5.50B est: 5.46B (+0.8%)	6.27B est: 5.79B (+8.3%)	6.70B est: 6.81B (-1.5%)	7.25B est: 6.90B (+5.1%)	7.46B est: 7.09B (+5.2%)	7.37B est: 7.19B (+2.5%)	7.51B est: 7.35B (+2.1%)	7.38B est: 7.29B (+1.2%)	7.15B est: 7.62B (-6.3%)	7.44B est: 7.38B (+0.8%)	7.49B est: 7.49B (0.0%)	7.52B est: 7.51B (+0.1%)	7.71B est: 7.71B (+0.0%)	7.53B est: 7.57B (-0.5%)	7.73B est: 7.72B (+0.1%)	9.44B est: 9.34B (+1.0%)	10.79B est: 10.74B (+0.4%)	9.88B est: 9.83B (+0.5%)	9.25B est: 9.35B (-1.0%)	9.87B est: 9.83B (+0.4%)	11.04B est: 10.98B (+0.5%)	11.85B 11.76B – 11.90B +7.9% YoY	12.38B 12.19B – 12.60B +4.5% YoY	12.93B 12.90B – 12.95B +4.4% YoY	13.72B 13.57B – 13.88B +6.1% YoY	11.56B 11.43B – 11.69B -15.8% YoY
EBITDA	559.12M est: 410.11M (+36.3%)	723.84M est: 624.05M (+16.0%)	950.36M est: 860.21M (+10.5%)	1.05B est: 994.28M (+5.6%)	1.18B est: 1.09B (+8.3%)	1.33B est: 1.08B (+23.0%)	1.33B est: 942.44M (+41.0%)	1.50B est: 1.17B (+28.5%)	1.63B est: 1.52B (+7.6%)	1.59B est: 1.51B (+5.2%)	1.30B est: 1.21B (+7.6%)	1.52B est: 1.39B (+9.5%)	1.79B est: 1.93B (-6.9%)	1.30B est: 1.29B (+1.4%)	1.56B est: 1.52B (+2.2%)	1.48B est: 1.44B (+2.5%)	1.45B est: 1.34B (+8.3%)	1.40B est: 1.39B (+0.8%)	1.59B est: 1.56B (+1.6%)	2.41B est: 2.21B (+9.0%)	3.16B est: 2.71B (+16.6%)	1.82B est: 2.22B (-18.0%)	1.73B est: 1.97B (-12.2%)	1.89B est: 2.07B (-8.7%)	2.19B est: 2.32B (-5.3%)	2.50B 2.48B – 2.51B +7.9% YoY	2.61B 2.57B – 2.66B +4.5% YoY	2.73B 2.72B – 2.73B +4.4% YoY	2.89B 2.86B – 2.93B +6.1% YoY	2.44B 2.41B – 2.47B -15.8% YoY
EBIT	411.39M est: 367.78M (+11.9%)	592.45M est: 548.28M (+8.1%)	796.45M est: 767.66M (+3.8%)	880.85M est: 893.01M (-1.4%)	1.01B est: 974.09M (+3.4%)	1.13B est: 990.44M (+13.9%)	1.09B est: 1.09B (-0.1%)	1.20B est: 1.16B (+3.9%)	1.37B est: 1.29B (+6.8%)	1.32B est: 1.26B (+4.6%)	1.02B est: 939.26M (+8.7%)	1.24B est: 1.19B (+4.3%)	1.49B est: 1.59B (-6.4%)	990.00M est: 972.89M (+1.8%)	1.26B est: 1.38B (-9.0%)	1.23B est: 1.26B (-2.2%)	1.18B est: 1.09B (+8.8%)	1.10B est: 1.10B (-0.4%)	1.26B est: 1.19B (+5.6%)	2.05B est: 1.80B (+13.7%)	2.75B est: 2.04B (+34.5%)	1.38B est: 1.85B (-25.3%)	1.29B est: 1.54B (-16.0%)	1.40B est: 1.62B (-13.5%)	1.62B est: 1.81B (-10.3%)	1.95B 1.94B – 1.96B +7.9% YoY	2.04B 2.01B – 2.08B +4.5% YoY	2.13B 2.13B – 2.13B +4.4% YoY	2.26B 2.24B – 2.29B +6.1% YoY	1.90B 1.88B – 1.93B -15.8% YoY
Net Income	162.30M est: 145.05M (+11.9%)	322.15M est: 298.45M (+7.9%)	436.72M est: 421.37M (+3.6%)	499.20M est: 494.53M (+0.9%)	546.28M est: 549.51M (-0.6%)	586.42M est: 537.27M (+9.1%)	339.94M est: 343.67M (-1.1%)	581.50M est: 549.60M (+5.8%)	729.10M est: 698.86M (+4.3%)	720.90M est: 701.38M (+2.8%)	470.60M est: 433.32M (+8.6%)	555.70M est: 546.82M (+1.6%)	849.00M est: 917.45M (-7.5%)	556.00M est: 548.52M (+1.4%)	709.00M est: 701.07M (+1.1%)	645.00M est: 633.32M (+1.8%)	772.00M est: 725.03M (+6.5%)	736.00M est: 734.61M (+0.2%)	858.00M est: 829.09M (+3.5%)	1.43B est: 1.30B (+9.8%)	2.00B est: 1.71B (+16.5%)	946.00M est: 1.31B (-27.6%)	854.00M est: 836.00M (+2.2%)	871.00M est: 1.01B (-13.4%)	992.00M est: 1.11B (-10.5%)	1.21B 1.19B – 1.23B +9.3% YoY	1.33B 1.29B – 1.36B +9.7% YoY	1.44B 1.36B – 1.53B +8.7% YoY	1.61B 1.59B – 1.64B +11.7% YoY	1.67B 1.65B – 1.70B +3.9% YoY
SGA	1.02B est: 976.41M (+4.3%)	1.07B est: 1.00B (+7.4%)	1.17B est: 1.13B (+3.0%)	1.23B est: 1.21B (+1.4%)	1.26B est: 1.29B (-2.1%)	1.43B est: 1.35B (+6.0%)	1.61B est: 1.66B (-2.9%)	1.74B est: 1.68B (+3.4%)	1.75B est: 1.68B (+3.9%)	1.71B est: 1.71B (-0.1%)	1.81B est: 2.08B (-12.9%)	1.75B est: 1.79B (-2.5%)	1.70B est: 1.92B (-11.3%)	1.73B est: 1.80B (-4.0%)	1.68B est: 1.75B (-4.2%)	1.68B est: 1.71B (-1.9%)	1.75B est: 1.71B (+2.6%)	1.42B est: 1.50B (-4.9%)	1.46B est: 1.41B (+3.3%)	1.55B est: 1.47B (+5.5%)	1.73B est: 1.49B (+15.7%)	1.87B est: 1.57B (+19.1%)	1.62B est: 1.65B (-2.0%)	1.77B est: 1.73B (+2.1%)	1.97B est: 1.94B (+1.5%)	2.09B 2.07B – 2.10B +7.9% YoY	2.18B 2.15B – 2.22B +4.5% YoY	2.28B 2.28B – 2.28B +4.4% YoY	2.42B 2.39B – 2.45B +6.1% YoY	2.04B 2.02B – 2.06B -15.8% YoY
EPS	0.87 est: 0.79 (+10.1%)	1.67 est: 1.40 (+19.3%)	2.11 est: 1.92 (+9.9%)	2.45 est: 2.38 (+2.9%)	2.71 est: 2.70 (+0.4%)	2.98 est: 2.68 (+11.2%)	1.76 est: 2.94 (-40.1%)	2.99 est: 2.94 (+1.7%)	3.91 est: 3.50 (+11.7%)	4.08 est: 3.85 (+6.0%)	2.95 est: 4.17 (-29.3%)	3.49 est: 4.33 (-19.4%)	5.58 est: 4.50 (+24.0%)	3.83 est: 4.02 (-4.7%)	4.92 est: 4.77 (+3.1%)	4.58 est: 5.10 (-10.2%)	5.63 est: 5.65 (-0.3%)	5.41 est: 6.33 (-14.6%)	6.38 est: 6.49 (-1.8%)	10.68 est: 10.80 (-1.1%)	15.90 est: 14.12 (+12.6%)	8.12 est: 9.85 (-17.5%)	7.59 est: 7.50 (+1.2%)	7.80 est: 8.90 (-12.4%)	8.87 est: 9.81 (-9.6%)	10.75 10.57 – 10.87 +9.5% YoY	11.67 11.44 – 12.06 +8.6% YoY	12.73 12.02 – 13.52 +9.0% YoY	14.26 14.07 – 14.48 +12.1% YoY	14.82 14.62 – 15.05 +3.9% YoY

Recent Grade Changes (3M)

Date	Firm	Previous	New Grade	Action
2026-04-22	Baird	Neutral	Neutral	Maintain

Historical Ratings (3M)

Date	Rating	Overall	DCF	ROE	ROA	D/E	P/E	P/B
2026-05-28	B+	3/5	4/5	4/5	5/5	1/5	2/5	2/5
2026-05-27	B+	3/5	4/5	4/5	5/5	1/5	2/5	2/5
2026-05-26	B+	3/5	4/5	4/5	5/5	1/5	2/5	2/5
2026-05-22	B+	3/5	4/5	4/5	5/5	1/5	2/5	2/5
2026-05-21	B+	3/5	4/5	4/5	5/5	1/5	2/5	2/5
2026-05-20	B+	3/5	4/5	4/5	5/5	1/5	2/5	2/5
2026-05-19	B+	3/5	4/5	4/5	5/5	1/5	2/5	2/5
2026-05-18	B+	3/5	4/5	4/5	5/5	1/5	2/5	2/5
2026-05-15	B+	3/5	4/5	4/5	5/5	1/5	2/5	2/5
2026-05-14	B+	3/5	4/5	4/5	5/5	1/5	2/5	2/5
2026-05-13	B+	3/5	4/5	4/5	5/5	1/5	2/5	2/5
2026-05-12	B+	3/5	4/5	4/5	5/5	1/5	2/5	2/5
2026-05-11	B+	3/5	4/5	4/5	5/5	1/5	2/5	2/5
2026-05-08	A-	4/5	4/5	4/5	5/5	1/5	3/5	3/5
2026-05-07	A-	4/5	4/5	4/5	5/5	1/5	3/5	3/5
2026-05-06	A-	4/5	4/5	4/5	5/5	1/5	3/5	3/5
2026-05-05	B+	3/5	4/5	4/5	5/5	1/5	3/5	2/5
2026-05-04	B+	3/5	4/5	4/5	5/5	1/5	3/5	2/5
2026-05-01	B+	3/5	4/5	4/5	5/5	1/5	3/5	2/5
2026-04-30	B+	3/5	4/5	4/5	5/5	1/5	3/5	2/5
2026-04-29	B+	3/5	4/5	4/5	5/5	1/5	3/5	2/5
2026-04-28	B+	3/5	4/5	4/5	5/5	1/5	3/5	2/5
2026-04-27	B+	3/5	4/5	4/5	5/5	1/5	3/5	2/5
2026-04-24	B+	3/5	4/5	4/5	5/5	1/5	3/5	2/5
2026-04-23	B+	3/5	4/5	4/5	5/5	1/5	3/5	2/5
2026-04-22	B+	3/5	4/5	4/5	5/5	1/5	3/5	2/5
2026-04-21	B+	3/5	4/5	4/5	5/5	1/5	3/5	2/5
2026-04-20	A-	4/5	4/5	4/5	5/5	1/5	3/5	3/5
2026-04-17	A-	4/5	4/5	4/5	5/5	1/5	3/5	3/5
2026-04-16	A-	4/5	4/5	4/5	5/5	1/5	3/5	3/5
2026-04-15	A-	4/5	4/5	4/5	5/5	1/5	3/5	3/5

Owner Earnings

Owner's Earnings (history) From To

Owner alignment

Owner's Earnings TTM

1.60B

OE per share TTM

14.24

Owner's Yield

7.48%

Maintenance CapEx ratio

21.27%

Maint CapEx / Avg PPE

24.9%

Ownership Overview

Ownership breakdown

At a glance

Institutional holders

1,071

Total invested

19.99B

Insider transactions (90d)

Beneficial owners (>5%)

#	Reporting person ⇅	Amount owned ⇅	% of class ⇅	Sole voting ⇅	Shared voting ⇅	Sole dispositive ⇅	Shared dispositive ⇅	Type	Citizenship	Filing date ⇅	SEC filing
1	The Vanguard Group - 23-1945930	13.38M	10.91%	—	196.9K	12.88M	497.3K	IA	Pennsylvania	2022-02-10	↗
2	(1) BlackRock, Inc.	12.81M	10.70%	11.66M	—	12.81M	—	HC	Delaware	2022-04-08	↗
3	Edward C. Johnson 3d	7.74M	5.32%	—	—	7.74M	—	IN	Delaware	2014-02-14	↗
4	STATE STREET CORPORATION	6.27M	5.11%	—	—	—	—	HC	BOSTON, MASSACHUSETTS	2022-02-10	↗
5	The Column Group, LP	3.16M	7.00%	219.8K	27.2K	13.65M	245.0K	PN	Pennsylvania	2017-03-10	↗
6	B. Riley Financial, Inc.	2.89M	4.80%	—	—	—	—	HC	MARYLAND	2016-02-09	↗
7	Delaware Management Holdings	928.8K	4.37%	245.6K	—	10.91M	238.1K	HC	Pennsylvania	2015-02-10	↗
8	10.	20.2K	0.01%	20.2K	—	20.2K	—	CO	Sydney, New South Wales Australia	2020-02-13	↗
9	19,550	19.6K	0.01%	19.6K	—	19.6K	—	CO	Sydney, New South Wales Australia	2019-02-14	↗
10	0.00%	3.2K	0.00%	3.2K	—	3.2K	—	CO	Sydney, New South Wales Australia	2019-02-14	↗

Institutional Activity (13F)

Institutional ownership trend From To

13F snapshot — 2026 Q1

Investors holding

1,071

+4 vs prev Q

New positions

124

Closed positions

115

Increased

477

Reduced

371

Put/Call ratio

0.41

Calls held

405.2K

Puts held

164.2K

Top institutional holders

#	Investor ⇅	Shares / Δ ⇅	Mkt value / Δ ⇅	Own% / Δ ⇅	Weight% / Δ ⇅	Avg px / Perf. ⇅	Hold / Status ⇅
1	MACQUARIE MANAGEMENT HOLDINGS, INC.	246.1K +246.1K (+100.0%)	42.70B +42.7B (+100.0%)	0.22% +0.222 pp	0.06% +0.064 pp	USD173.53 +0.0%	1 qtrs NEW
2	VANGUARD GROUP INC	14.39M +140.5K (+1.0%)	2.50B -218.6M (-8.0%)	12.97% +0.241 pp	0.04% -0.005 pp	USD76.37 +127.2%	84 qtrs —
3	BLACKROCK, INC.	9.46M -542.8K (-5.4%)	1.64B -264.7M (-13.9%)	8.52% -0.409 pp	0.03% -0.006 pp	USD155.76 +11.4%	6 qtrs —
4	PRICE T ROWE ASSOCIATES INC /MD/	6.30M -708.8K (-10.1%)	1.09B -242.5M (-18.2%)	5.67% -0.582 pp	0.12% -0.025 pp	USD158.86 +9.2%	75 qtrs —
5	STATE STREET CORP	5.38M +158.6K (+3.0%)	934.03M -61.5M (-6.2%)	4.85% +0.185 pp	0.03% -0.003 pp	USD77.16 +124.9%	51 qtrs —
6	JPMORGAN CHASE & CO	4.15M -171.5K (-4.0%)	719.44M -103.4M (-12.6%)	3.70% -0.153 pp	0.05% -0.004 pp	USD153.82 +12.8%	51 qtrs —
7	BOSTON PARTNERS	3.91M -123.6K (-3.1%)	680.02M -88.0M (-11.5%)	3.53% -0.079 pp	0.70% -0.084 pp	USD176.40 -1.6%	4 qtrs —
8	GEODE CAPITAL MANAGEMENT, LLC	3.03M -8.3K (-0.3%)	523.52M -52.9M (-9.2%)	2.73% +0.017 pp	0.03% -0.005 pp	USD104.45 +66.1%	78 qtrs —
9	MORGAN STANLEY	2.69M +406.7K (+17.8%)	467.42M +31.6M (+7.2%)	2.43% +0.385 pp	0.03% +0.002 pp	USD144.22 +20.3%	51 qtrs —
10	VICTORY CAPITAL MANAGEMENT INC	2.13M -217.6K (-9.3%)	369.00M -77.7M (-17.4%)	1.92% -0.177 pp	0.21% -0.053 pp	USD113.50 +52.9%	43 qtrs —
11	DIMENSIONAL FUND ADVISORS LP	1.93M +24.0K (+1.3%)	335.20M -28.3M (-7.8%)	1.74% +0.037 pp	0.07% -0.008 pp	USD85.76 +102.3%	51 qtrs —
12	GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC	1.82M +69.7K (+4.0%)	315.14M -17.7M (-5.3%)	1.64% +0.077 pp	0.81% -0.133 pp	USD111.40 +55.8%	24 qtrs —
13	WELLS FARGO & COMPANY/MN	1.77M -36.2K (-2.0%)	306.99M -37.1M (-10.8%)	1.59% -0.018 pp	0.06% -0.010 pp	USD142.54 +21.7%	57 qtrs —
14	GOLDMAN SACHS GROUP INC	1.71M +645.2K (+60.7%)	296.55M +93.8M (+46.3%)	1.53% +0.576 pp	0.04% +0.012 pp	USD162.34 +6.9%	73 qtrs —
15	INVESCO LTD.	1.67M -21.8K (-1.3%)	289.27M -32.6M (-10.1%)	1.50% -0.006 pp	0.04% -0.006 pp	USD143.75 +20.7%	57 qtrs —
16	EDGEPOINT INVESTMENT GROUP INC.	1.66M +811.3K (+95.5%)	288.25M +126.3M (+78.0%)	1.50% +0.738 pp	2.37% +1.158 pp	USD182.24 -4.8%	3 qtrs —
17	BANK OF AMERICA CORP /DE/	1.62M -12.1K (-0.7%)	281.63M -30.0M (-9.6%)	1.46% +0.002 pp	0.02% -0.001 pp	USD148.23 +17.1%	52 qtrs —
18	DAVIS SELECTED ADVISERS	1.59M +228.3K (+16.8%)	275.90M +16.4M (+6.3%)	1.42% +0.204 pp	1.24% -0.115 pp	USD119.40 +45.3%	48 qtrs —
19	NORGES BANK	1.32M +1.3M (+100.0%)	229.52M +229.5M (+100.0%)	1.19% +1.192 pp	0.02% +0.025 pp	USD173.53 +0.0%	1 qtrs NEW
20	FMR LLC	1.20M -11.1K (-0.9%)	208.63M -22.6M (-9.8%)	1.08% 0.000 pp	0.01% -0.001 pp	USD141.67 +22.5%	70 qtrs —
21	UBS GROUP AG	1.11M +450.2K (+67.8%)	193.39M +66.8M (+52.8%)	1.00% +0.411 pp	0.03% +0.012 pp	USD156.03 +11.2%	45 qtrs —
22	NORTHERN TRUST CORP	1.08M -74.8K (-6.5%)	187.16M -32.6M (-14.8%)	0.97% -0.058 pp	0.02% -0.004 pp	USD89.23 +94.5%	51 qtrs —
23	FIDUCIARY MANAGEMENT INC /WI/	1.05M -100.6K (-8.8%)	181.67M -37.0M (-16.9%)	0.94% -0.081 pp	2.00% -0.215 pp	USD134.77 +28.8%	8 qtrs —
24	M&G PLC	945.1K -145.3K (-13.3%)	164.44M -43.8M (-21.0%)	0.85% -0.122 pp	0.84% -0.263 pp	USD167.43 +3.6%	8 qtrs —
25	AMERICAN CENTURY COMPANIES INC	870.5K +1.4K (+0.2%)	151.06M -14.6M (-8.8%)	0.78% +0.008 pp	0.08% -0.008 pp	USD130.62 +32.9%	51 qtrs —
26	UBS ASSET MANAGEMENT AMERICAS INC	846.9K -54.7K (-6.1%)	146.97M -24.9M (-14.5%)	0.76% -0.042 pp	0.03% -0.006 pp	USD130.19 +33.3%	90 qtrs —
27	AMERIPRISE FINANCIAL INC	813.5K -39.4K (-4.6%)	141.16M -21.4M (-13.1%)	0.73% -0.029 pp	0.03% -0.005 pp	USD129.10 +34.4%	55 qtrs —
28	CHARLES SCHWAB INVESTMENT MANAGEMENT INC	751.1K +4.0K (+0.5%)	130.33M -12.0M (-8.5%)	0.68% +0.010 pp	0.02% -0.003 pp	USD90.12 +92.6%	100 qtrs —
29	LEGAL & GENERAL GROUP PLC	743.0K -12.7K (-1.7%)	128.93M -15.1M (-10.5%)	0.67% -0.005 pp	0.03% -0.004 pp	USD92.54 +87.5%	75 qtrs —
30	QUBE RESEARCH & TECHNOLOGIES LTD	733.5K +203.7K (+38.4%)	127.28M +26.3M (+26.1%)	0.66% +0.188 pp	0.13% +0.025 pp	USD164.00 +5.8%	12 qtrs —
31	BANK OF NEW YORK MELLON CORP	670.7K -150.8K (-18.4%)	116.39M -40.2M (-25.7%)	0.60% -0.129 pp	0.02% -0.010 pp	USD99.03 +75.2%	66 qtrs —
32	DEKABANK DEUTSCHE GIROZENTRALE	748.7K +— (+0.0%)	114.35M -26.6M (-18.9%)	0.67% +0.006 pp	0.20% -0.040 pp	USD125.74 +38.0%	65 qtrs —
33	ALLIANCEBERNSTEIN L.P.	632.4K -2.4K (-0.4%)	109.74M -11.2M (-9.3%)	0.57% +0.003 pp	0.03% -0.003 pp	USD141.49 +22.6%	61 qtrs —
34	DEUTSCHE BANK AG\	609.1K +84.9K (+16.2%)	105.69M +5.8M (+5.8%)	0.54% +0.076 pp	0.03% +0.001 pp	USD134.38 +29.1%	50 qtrs —
35	SQUAREPOINT OPS LLC	565.8K -71.5K (-11.2%)	98.18M -23.3M (-19.2%)	0.51% -0.059 pp	0.10% -0.018 pp	USD177.60 -2.3%	35 qtrs —
36	PRINCIPAL FINANCIAL GROUP INC	531.3K -3.2K (-0.6%)	92.20M -9.7M (-9.5%)	0.47% -0.003 pp	0.05% -0.004 pp	USD131.98 +31.5%	81 qtrs —
37	CRAWFORD INVESTMENT COUNSEL INC	496.5K +2.1K (+0.4%)	86.16M -8.1M (-8.6%)	0.45% +0.006 pp	1.43% -0.128 pp	USD136.80 +26.8%	8 qtrs —
38	AMUNDI	464.2K +36.6K (+8.6%)	80.55M +4.3M (+5.6%)	0.42% +0.036 pp	0.02% -0.003 pp	USD139.86 +24.1%	19 qtrs —
39	RAYMOND JAMES FINANCIAL INC	463.3K +5.2K (+1.1%)	80.39M -6.9M (-7.9%)	0.42% +0.008 pp	0.03% -0.003 pp	USD154.49 +12.3%	5 qtrs —
40	ARTEMIS INVESTMENT MANAGEMENT LLP	460.7K +29.1K (+6.7%)	79.95M -2.3M (-2.8%)	0.41% +0.026 pp	0.97% -0.058 pp	USD184.19 -5.8%	3 qtrs —
41	PACER ADVISORS, INC.	447.7K -3.2K (-0.7%)	77.69M -8.2M (-9.6%)	0.40% -0.003 pp	0.20% -0.018 pp	USD189.70 -8.5%	41 qtrs —
42	CITADEL ADVISORS LLC	425.2K +294.6K (+225.6%)	73.79M +48.9M (+196.4%)	0.38% +0.267 pp	0.01% +0.007 pp	USD177.35 -2.2%	35 qtrs —
43	FIRST TRUST ADVISORS LP	351.7K -19.8K (-5.3%)	61.03M -9.8M (-13.8%)	0.32% -0.015 pp	0.04% -0.008 pp	USD124.08 +39.9%	51 qtrs —
44	CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM	350.2K +11.3K (+3.3%)	60.78M -3.8M (-5.9%)	0.32% +0.013 pp	0.03% -0.004 pp	USD88.99 +95.0%	58 qtrs —
45	WOODLINE PARTNERS LP	341.4K +223.9K (+190.7%)	59.24M +36.9M (+164.7%)	0.31% +0.203 pp	0.23% +0.124 pp	USD161.16 +7.7%	8 qtrs —
46	NUVEEN, LLC	334.0K -4.2K (-1.2%)	57.96M -6.5M (-10.1%)	0.30% -0.001 pp	0.02% -0.002 pp	USD169.53 +2.4%	4 qtrs —
47	ENVESTNET ASSET MANAGEMENT INC	333.8K -44.4K (-11.7%)	57.92M -14.1M (-19.6%)	0.30% -0.037 pp	0.02% -0.004 pp	USD142.34 +21.9%	51 qtrs —
48	BARCLAYS PLC	333.3K +34.4K (+11.5%)	57.84M +11.4M (+24.6%)	0.30% +0.033 pp	0.01% +0.002 pp	USD150.54 +15.3%	51 qtrs —
49	D. E. SHAW & CO., INC.	328.7K +328.7K (+100.0%)	57.05M +57.0M (+100.0%)	0.30% +0.296 pp	0.03% +0.031 pp	USD173.53 +0.0%	1 qtrs NEW
50	GREAT WEST LIFE ASSURANCE CO /CAN/	319.3K -123.4K (-27.9%)	55.43M -28.2M (-33.7%)	0.29% -0.108 pp	0.10% -0.023 pp	USD123.54 +40.5%	63 qtrs —
51	ADVISORS CAPITAL MANAGEMENT, LLC	313.8K +16.2K (+5.4%)	54.46M -2.3M (-4.0%)	0.28% +0.015 pp	0.64% -0.062 pp	USD143.63 +20.8%	36 qtrs —
52	CITIGROUP INC	309.8K -9.5K (-3.0%)	53.76M -7.1M (-11.7%)	0.28% -0.006 pp	0.02% -0.003 pp	USD163.05 +6.4%	108 qtrs —
53	FREESTONE GROVE PARTNERS LP	309.2K +309.2K (+100.0%)	53.66M +53.7M (+100.0%)	0.28% +0.279 pp	0.39% +0.388 pp	USD173.53 +0.0%	1 qtrs NEW
54	SWISS NATIONAL BANK	306.5K -15.3K (-4.8%)	53.19M -8.1M (-13.3%)	0.28% -0.011 pp	0.03% -0.004 pp	USD91.92 +88.8%	51 qtrs —
55	JANE STREET GROUP, LLC	292.7K +219.6K (+300.1%)	50.80M +36.9M (+264.3%)	0.26% +0.196 pp	0.01% +0.006 pp	USD177.03 -2.0%	28 qtrs —
56	SUMITOMO MITSUI TRUST HOLDINGS, INC.	277.2K -1.5K (-0.5%)	48.10M -5.0M (-9.4%)	0.25% -0.001 pp	0.03% -0.002 pp	USD102.41 +69.4%	59 qtrs —
57	RHUMBLINE ADVISERS	276.5K +2.0K (+0.7%)	47.97M -4.3M (-8.3%)	0.25% +0.004 pp	0.04% -0.003 pp	USD88.82 +95.4%	51 qtrs —
58	QUANTINNO CAPITAL MANAGEMENT LP	269.6K +76.1K (+39.3%)	46.78M +9.9M (+26.9%)	0.24% +0.070 pp	0.09% -0.007 pp	USD181.16 -4.2%	17 qtrs —
59	SCHRODER INVESTMENT MANAGEMENT GROUP	257.4K -57.1K (-18.1%)	45.17M -14.2M (-23.9%)	0.23% -0.049 pp	0.03% -0.012 pp	USD168.80 +2.8%	51 qtrs —
60	—	249.2K +249.2K (+100.0%)	43.24M +43.2M (+100.0%)	0.22% +0.225 pp	0.13% +0.135 pp	USD173.53 +0.0%	1 qtrs NEW
61	MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD.	229.4K +5.0K (+2.2%)	39.87M -2.9M (-6.8%)	0.20% +0.005 pp	0.03% -0.004 pp	USD139.50 +24.4%	58 qtrs —
62	ROYAL BANK OF CANADA	228.7K -243.5K (-51.6%)	39.69M -50.3M (-55.9%)	0.21% -0.216 pp	0.01% -0.008 pp	USD161.23 +7.6%	51 qtrs —
63	BNP PARIBAS ARBITRAGE, SNC	228.1K +6.5K (+2.9%)	39.57M -2.7M (-6.3%)	0.21% +0.008 pp	0.02% -0.005 pp	USD139.45 +24.4%	50 qtrs —
64	HSBC HOLDINGS PLC	227.1K +14.4K (+6.8%)	39.49M -1.0M (-2.6%)	0.20% +0.013 pp	0.02% -0.002 pp	USD130.26 +33.2%	56 qtrs —
65	BNP PARIBAS ASSET MANAGEMENT HOLDING S.A.	225.3K -60.8K (-21.2%)	39.10M -15.1M (-27.9%)	0.20% -0.052 pp	0.04% -0.096 pp	USD166.98 +3.9%	51 qtrs —
66	BANK OF MONTREAL /CAN/	217.4K +14.8K (+7.3%)	37.72M -889.2K (-2.3%)	0.20% +0.015 pp	0.01% -0.002 pp	USD126.92 +36.7%	51 qtrs —
67	ACADIAN ASSET MANAGEMENT LLC	191.0K +188.2K (+6,735.2%)	33.13M +32.6M (+6,139.0%)	0.17% +0.170 pp	0.05% +0.054 pp	USD173.01 +0.3%	50 qtrs —
68	BAHL & GAYNOR INC	187.3K -29.4K (-13.6%)	32.50M -8.8M (-21.3%)	0.17% -0.025 pp	0.16% -0.041 pp	USD133.96 +29.5%	40 qtrs —
69	SG AMERICAS SECURITIES, LLC	179.7K +157.0K (+694.2%)	31.18M +26.9M (+623.2%)	0.16% +0.140 pp	0.04% +0.025 pp	USD173.87 -0.2%	51 qtrs —
70	VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V.	175.1K -166.5K (-48.7%)	30.39M -34.7M (-53.3%)	0.16% -0.147 pp	0.26% -0.321 pp	USD141.64 +22.5%	7 qtrs —
71	CONNING INC.	173.3K +173.3K (+100.0%)	30.07M +30.1M (+100.0%)	0.15% +0.155 pp	1.01% +1.007 pp	USD173.53 +0.0%	1 qtrs NEW
72	ANTIPODES PARTNERS LTD	172.0K +110.3K (+178.7%)	29.85M +18.1M (+153.8%)	0.15% +0.099 pp	0.63% +0.363 pp	USD179.54 -3.3%	4 qtrs —
73	APG ASSET MANAGEMENT N.V.	197.9K -15.1K (-7.1%)	29.24M -5.3M (-15.4%)	0.18% -0.012 pp	0.08% -0.014 pp	USD146.91 +18.1%	51 qtrs —
74	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	168.4K +164.0K (+3,703.9%)	29.22M +28.4M (+3,363.6%)	0.15% +0.148 pp	0.05% +0.047 pp	USD173.61 0.0%	4 qtrs —
75	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	168.0K -4.7K (-2.7%)	29.15M -3.8M (-11.4%)	0.15% -0.003 pp	0.03% -0.005 pp	USD81.84 +112.0%	52 qtrs —
76	PICTET ASSET MANAGEMENT HOLDING SA	162.3K -47.7K (-22.7%)	28.16M -11.8M (-29.6%)	0.14% -0.043 pp	0.03% -0.011 pp	USD133.19 +30.3%	10 qtrs —
77	COOKSON PEIRCE & CO INC	161.5K -2.3K (-1.4%)	28.03M -3.2M (-10.2%)	0.15% -0.001 pp	1.16% -0.119 pp	USD169.20 +2.6%	4 qtrs —
78	COPELAND CAPITAL MANAGEMENT, LLC	159.6K -8.7K (-5.2%)	27.70M -4.4M (-13.7%)	0.14% -0.008 pp	0.62% -0.050 pp	USD111.08 +56.2%	44 qtrs —
79	SUSQUEHANNA INTERNATIONAL GROUP, LLP	154.6K -50.1K (-24.5%)	26.83M -12.2M (-31.2%)	0.14% -0.044 pp	0.00% -0.001 pp	USD160.36 +8.2%	51 qtrs —
80	COLONY GROUP, LLC	154.0K +12.6K (+8.9%)	26.72M -219.3K (-0.8%)	0.14% +0.013 pp	0.03% -0.013 pp	USD176.09 -1.5%	8 qtrs —
81	BRAUN STACEY ASSOCIATES INC	153.9K -515.0 (-0.3%)	26.70M -2.7M (-9.3%)	0.14% -0.001 pp	0.87% -0.098 pp	USD180.94 -4.1%	3 qtrs —
82	CREDIT AGRICOLE S A	152.3K +95.5K (+168.0%)	26.43M +15.6M (+144.0%)	0.14% +0.087 pp	0.06% +0.031 pp	USD179.89 -3.5%	2 qtrs —
83	WILLIS INVESTMENT COUNSEL	151.8K +— (+0.0%)	26.34M -2.6M (-8.9%)	0.14% +0.000 pp	1.36% -0.221 pp	USD116.95 +48.4%	29 qtrs —
84	SKANDINAVISKA ENSKILDA BANKEN AB (PUBL)	139.9K -22.0K (-13.6%)	24.28M -6.6M (-21.3%)	0.13% -0.019 pp	0.10% -0.026 pp	USD167.10 +3.8%	41 qtrs —
85	ACHMEA INVESTMENT MANAGEMENT B.V.	138.0K -6.2K (-4.3%)	23.95M -3.5M (-12.9%)	0.12% -0.004 pp	0.61% +0.270 pp	USD153.86 +12.8%	36 qtrs —
86	VIRGINIA RETIREMENT SYSTEMS ET AL	123.9K +— (+0.0%)	21.50M -2.1M (-8.9%)	0.11% +0.000 pp	0.13% -0.025 pp	USD169.20 +2.6%	4 qtrs —
87	UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH	119.9K -67.2K (-35.9%)	20.90M -14.8M (-41.4%)	0.11% -0.060 pp	0.03% -0.025 pp	USD150.86 +15.0%	5 qtrs —
88	STIFEL FINANCIAL CORP	113.0K +80.0 (+0.1%)	19.62M -1.9M (-8.9%)	0.10% +0.001 pp	0.02% -0.002 pp	USD127.06 +36.6%	48 qtrs —
89	SILVERCREST ASSET MANAGEMENT GROUP LLC	112.3K +2.9K (+2.7%)	19.48M -1.4M (-6.5%)	0.10% +0.004 pp	0.13% -0.004 pp	USD156.13 +11.1%	20 qtrs —
90	WILEY BROS.-AINTREE CAPITAL, LLC	111.1K +10.1K (+10.0%)	19.29M -28.6K (-0.1%)	0.10% +0.010 pp	0.10% -0.023 pp	USD173.31 +0.1%	7 qtrs —
91	ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V.	109.5K -1.9K (-1.7%)	19.00M -2.2M (-10.5%)	0.10% -0.002 pp	0.03% -0.004 pp	USD141.82 +22.4%	71 qtrs —
92	TOCQUEVILLE ASSET MANAGEMENT L.P.	109.2K -340.0 (-0.3%)	18.95M -1.9M (-9.2%)	0.10% +0.001 pp	0.28% -0.027 pp	USD64.95 +167.2%	53 qtrs —
93	MACKENZIE FINANCIAL CORP	104.8K -52.5K (-33.4%)	18.36M -11.6M (-38.8%)	0.09% -0.046 pp	0.02% -0.015 pp	USD176.14 -1.5%	48 qtrs —
94	ABRDN PLC	104.9K -775.0 (-0.7%)	18.20M -1.8M (-8.8%)	0.09% -0.001 pp	0.03% -0.003 pp	USD141.53 +22.6%	34 qtrs —
95	MORAN WEALTH MANAGEMENT, LLC	104.1K -1.1K (-1.0%)	18.06M -2.0M (-9.9%)	0.09% -0.001 pp	0.55% -0.051 pp	USD179.82 -3.5%	3 qtrs —
96	BLAIR WILLIAM & CO/IL	103.4K +5.5K (+5.6%)	17.94M -722.4K (-3.9%)	0.09% +0.006 pp	0.05% -0.002 pp	USD166.81 +4.0%	48 qtrs —
97	CANDRIAM S.C.A.	102.6K +30.8K (+42.9%)	17.81M +4.1M (+30.1%)	0.09% +0.028 pp	0.09% +0.017 pp	USD159.70 +8.7%	45 qtrs —
98	VOYA INVESTMENT MANAGEMENT LLC	101.6K -51.8K (-33.8%)	17.64M -11.6M (-39.7%)	0.09% -0.045 pp	0.02% -0.012 pp	USD176.79 -1.8%	51 qtrs —
99	POINT72 ASSET MANAGEMENT, L.P.	100.3K +100.3K (+100.0%)	17.41M +17.4M (+100.0%)	0.09% +0.090 pp	0.02% +0.020 pp	USD173.53 +0.0%	1 qtrs NEW

Ownership breakdown by holder

Insider Activity

Insider Activity — Latest Quarter

Ratio by transactions

0.00

Bearish

Buys

Sells

Shares acquired

11.9K

Shares disposed

—

Cash buys

—

Cash sales

—

Net activity

+11,932

Insider buys vs sells (history) From To

Recent insider transactions From To

Date	Person	Role	Transaction	A/D	Security	Shares	Price	Value	Owned after	D/I	Filing
2026-05-20	WENTWORTH TIMOTHY C	Director	A-Award	A	Common Stock	1,142	0.00	—	1,358	D	↗
2026-05-20	RING TIMOTHY M	Director	A-Award	A	Common Stock	1,142	0.00	—	31,140	D	↗
2026-05-20	PFEIFFER GARY M	Director	A-Award	A	Common Stock	1,142	0.00	—	31,005	D	↗
2026-05-20	MORRISON DENISE M	Director	A-Award	A	Common Stock	1,142	0.00	—	11,929	D	↗
2026-05-20	MAIN TIMOTHY L	Director	A-Award	A	Common Stock	1,142	0.00	—	27,439	D	↗
2026-05-20	Lassiter Wright III	Director	A-Award	A	Common Stock	1,142	0.00	—	10,317	D	↗
2026-05-20	Gregg Vicky B	Director	A-Award	A	Common Stock	1,142	0.00	—	18,314	D	↗
2026-05-20	Doi Tracey	Director	A-Award	A	Common Stock	1,142	0.00	—	7,748	D	↗
2026-05-20	Diaz Luis	Director	A-Award	A	Common Stock	1,142	0.00	—	5,196	D	↗
2026-05-20	CARTER ROBERT B	Director	A-Award	A	Common Stock	1,142	0.00	—	3,853	D	↗
2026-04-20	SAMAD SAM	Officer	A-Award	A	Common Stock	108	194.70	21.0K	33,376	D	↗
2026-04-20	Plewman Patrick	Officer	L-Small	A	Common Stock	49	194.70	9.5K	15,247	D	↗
2026-04-20	Lassiter Wright III	Director	L-Small	A	Common Stock	6	194.70	1.2K	9,063	D	↗
2026-04-20	KUPPUSAMY KARTHIK	Officer	L-Small	A	Common Stock	39	194.70	7.6K	13,490	D	↗
2026-04-20	Gregg Vicky B	Director	A-Award	A	Common Stock	68	194.70	13.2K	17,172	D	↗
2026-04-20	DELANEY MARK E	Officer	L-Small	A	Common Stock	37	194.70	7.2K	11,901	D	↗
2026-04-20	CARTER ROBERT B	Director	L-Small	A	Common Stock	7	194.70	1.4K	2,711	D	↗
2026-04-01	WENTWORTH TIMOTHY C	Director	A-Award	A	Phantom Stock Units	198	0.00	—	198	D	↗
2026-03-09	WENTWORTH TIMOTHY C	Director	A-Award	A	Common Stock	215	0.00	—	215	D	↗
2026-03-05	Plewman Patrick	Officer	S-Sale	D	Common Stock	2,855	206.21	588.7K	15,198	D	↗
2026-03-05	PREVOZNIK MICHAEL E	Officer	S-Sale	D	Common Stock	3,878	206.21	799.7K	37,557	D	↗
2026-03-05	Doherty Catherine T.	Officer	S-Sale	D	Common Stock	5,558	206.21	1.15M	67,122	D	↗
2026-03-04	SAMAD SAM	Officer	A-Award	A	Common Stock	13,947	204.86	2.86M	40,988	D	↗
2026-03-04	Plewman Patrick	Officer	A-Award	A	Common Stock	5,682	204.86	1.16M	20,880	D	↗
2026-03-04	PREVOZNIK MICHAEL E	Officer	F-InKind	D	Common Stock	3,354	204.86	687.1K	41,435	D	↗
2026-03-04	KUPPUSAMY KARTHIK	Officer	S-Sale	D	Common Stock	2,628	204.86	538.4K	13,441	D	↗
2026-03-04	Doherty Catherine T.	Officer	A-Award	A	Common Stock	11,364	204.86	2.33M	78,486	D	↗
2026-03-04	Deppe Michael J	Officer	F-InKind	D	Common Stock	750	204.86	153.6K	35,196	D	↗
2026-03-04	Davis J. E.	Director / Officer	F-InKind	D	Common Stock	26,414	204.86	5.41M	142,423	D	↗
2026-03-04	DELANEY MARK E	Officer	F-InKind	D	Common Stock	2,326	204.86	476.5K	11,864	D	↗
2026-03-03	Plewman Patrick	Officer	S-Sale	D	Common Stock	410	207.73	85.2K	15,198	D	↗
2026-03-03	PREVOZNIK MICHAEL E	Officer	S-Sale	D	Common Stock	526	207.73	109.3K	37,557	D	↗
2026-03-03	Doherty Catherine T.	Officer	S-Sale	D	Common Stock	632	207.73	131.3K	67,122	D	↗
2026-03-02	SAMAD SAM	Officer	F-InKind	D	Common Stock	869	204.86	178.0K	27,041	D	↗
2026-03-02	Plewman Patrick	Officer	F-InKind	D	Common Stock	230	204.86	47.1K	15,608	D	↗
2026-03-02	PREVOZNIK MICHAEL E	Officer	F-InKind	D	Common Stock	288	204.86	59.0K	38,083	D	↗
2026-03-02	KUPPUSAMY KARTHIK	Officer	F-InKind	D	Common Stock	205	204.86	42.0K	9,869	D	↗
2026-03-02	Doherty Catherine T.	Officer	F-InKind	D	Common Stock	648	204.86	132.7K	67,754	D	↗
2026-03-02	Deppe Michael J	Officer	F-InKind	D	Common Stock	88	204.86	18.0K	34,473	D	↗
2026-03-02	Davis J. E.	Director / Officer	S-Sale	D	Common Stock	10,000	212.52	2.13M	117,185	D	↗
2026-03-02	DELANEY MARK E	Officer	F-InKind	D	Common Stock	188	204.86	38.5K	8,508	D	↗
2026-02-19	Plewman Patrick	Officer	S-Sale	D	Common Stock	958	204.83	196.2K	15,838	D	↗
2026-02-19	PREVOZNIK MICHAEL E	Officer	S-Sale	D	Common Stock	1,111	204.83	227.6K	38,371	D	↗
2026-02-19	Doherty Catherine T.	Officer	S-Sale	D	Common Stock	1,433	204.83	293.5K	68,402	D	↗
2026-02-18	SAMAD SAM	Officer	A-Award	A	Non-Qualifed Stock Option (right to buy)	18,303	204.96	3.75M	18,303	D	↗
2026-02-18	Plewman Patrick	Officer	F-InKind	D	Common Stock	244	210.01	51.2K	17,089	D	↗
2026-02-18	PREVOZNIK MICHAEL E	Officer	A-Award	A	Non-Qualifed Stock Option (right to buy)	9,289	204.96	1.90M	9,289	D	↗
2026-02-18	KUPPUSAMY KARTHIK	Officer	F-InKind	D	Common Stock	252	210.01	52.9K	8,173	D	↗
2026-02-18	Doherty Catherine T.	Officer	F-InKind	D	Common Stock	433	210.01	90.9K	70,563	D	↗
2026-02-18	Deppe Michael J	Officer	A-Award	A	Common Stock	366	0.00	—	34,742	D	↗
2026-02-18	Davis J. E.	Director / Officer	A-Award	A	Non-Qualifed Stock Option (right to buy)	73,225	204.96	15.01M	73,225	D	↗
2026-02-18	DELANEY MARK E	Officer	F-InKind	D	Common Stock	205	210.01	43.1K	8,911	D	↗
2026-02-13	Doherty Catherine T.	Officer	S-Sale	D	Common Stock	3,500	207.08	724.8K	70,038	D	↗
2026-02-10	Plewman Patrick	Officer	M-Exempt	A	Common Stock	5,662	121.81	689.7K	21,043	D	↗
2026-01-28	SAMAD SAM	Officer	A-Award	A	Common Stock	69	183.51	12.7K	27,910	D	↗
2026-01-28	Plewman Patrick	Officer	A-Award	A	Common Stock	48	183.51	8.8K	15,381	D	↗
2026-01-28	Lassiter Wright III	Director	L-Small	A	Common Stock	7	183.51	1.3K	9,057	D	↗
2026-01-28	KUPPUSAMY KARTHIK	Officer	L-Small	A	Common Stock	16	183.52	2.9K	10,065	D	↗
2026-01-28	Gregg Vicky B	Director	L-Small	A	Common Stock	67	183.51	12.3K	17,104	D	↗
2026-01-28	DELANEY MARK E	Officer	L-Small	A	Common Stock	15	183.51	2.8K	8,696	D	↗
2026-01-28	CARTER ROBERT B	Director	L-Small	A	Common Stock	6	183.51	1.1K	2,704	D	↗
2025-11-25	Gregg Vicky B	Director	S-Sale	D	Common Stock	1,250	191.76	239.7K	17,037	D	↗
2025-11-25	Davis J. E.	Director / Officer	M-Exempt	D	Non-Qualifed Stock Option (right to buy)	55,093	95.80	5.28M	0	D	↗
2025-11-18	DELANEY MARK E	Officer	M-Exempt	A	Common Stock	100	143.33	14.3K	15,476	D	↗
2025-11-05	Davis J. E.	Director / Officer	F-InKind	D	Common Stock	7,143	175.57	1.25M	120,480	D	↗
2025-10-23	PFEIFFER GARY M	Director	I-Discretionary	D	Phantom Stock	4,413	0.00	—	0	D	↗
2025-10-22	PFEIFFER GARY M	Director	S-Sale	D	Common Stock	1,482	182.40	270.3K	29,431	D	↗
2025-10-21	SAMAD SAM	Officer	A-Award	A	Common Stock	68	189.08	12.9K	25,741	D	↗
2025-10-21	Plewman Patrick	Officer	A-Award	A	Common Stock	46	189.08	8.7K	15,333	D	↗
2025-10-21	KUPPUSAMY KARTHIK	Officer	A-Award	A	Common Stock	15	189.08	2.8K	8,379	D	↗
2025-10-21	Gregg Vicky B	Director	A-Award	A	Common Stock	70	189.08	13.2K	18,287	D	↗
2025-10-21	DELANEY MARK E	Officer	A-Award	A	Common Stock	15	189.08	2.8K	7,530	D	↗
2025-10-21	CARTER ROBERT B	Director	A-Award	A	Common Stock	6	189.09	1.1K	2,698	D	↗
2025-10-01	RING TIMOTHY M	Director	A-Award	A	Phantom Stock Units	233	0.00	—	17,036	D	↗
2025-10-01	Lassiter Wright III	Director	A-Award	A	Phantom Stock Units	157	0.00	—	679	D	↗
2025-09-26	PREVOZNIK MICHAEL E	Officer	M-Exempt	A	Common Stock	227	103.57	23.5K	38,344	D	↗
2025-09-24	PREVOZNIK MICHAEL E	Officer	M-Exempt	D	Non-Qualifed Stock Option (right to buy)	175	103.57	18.1K	227	D	↗
2025-09-23	PREVOZNIK MICHAEL E	Officer	S-Sale	D	Common Stock	28,288	187.12	5.29M	38,117	D	↗
2025-08-21	Plewman Patrick	Officer	S-Sale	D	Common Stock	1,975	185.00	365.4K	15,269	D	↗
2025-08-19	Plewman Patrick	Officer	M-Exempt	A	Common Stock	4,532	112.17	508.4K	21,776	D	↗
2025-08-15	Plewman Patrick	Officer	S-Sale	D	Common Stock	1,975	180.00	355.5K	17,244	D	↗
2025-08-13	KUPPUSAMY KARTHIK	Officer	F-InKind	D	Common Stock	123	175.91	21.6K	8,338	D	↗
2025-08-06	Plewman Patrick	Officer	M-Exempt	A	Common Stock	3,560	86.63	308.4K	24,745	D	↗
2025-07-31	KUPPUSAMY KARTHIK	Officer	S-Sale	D	Common Stock	2,210	170.00	375.7K	8,450	D	↗
2025-07-30	KUPPUSAMY KARTHIK	Officer	M-Exempt	D	Non-Qualifed Stock Option (right to buy)	5,224	112.17	586.0K	0	D	↗
2025-07-21	SAMAD SAM	Officer	L-Small	A	Common Stock	72	167.50	12.1K	25,673	D	↗
2025-07-21	Plewman Patrick	Officer	L-Small	A	Common Stock	80	167.49	13.4K	21,185	D	↗
2025-07-21	Lassiter Wright III	Director	L-Small	A	Common Stock	7	167.51	1.2K	9,044	D	↗
2025-07-21	KUPPUSAMY KARTHIK	Officer	L-Small	A	Common Stock	27	167.50	4.5K	10,660	D	↗
2025-07-21	Gregg Vicky B	Director	L-Small	A	Common Stock	79	167.50	13.2K	18,217	D	↗
2025-07-21	DELANEY MARK E	Officer	L-Small	A	Common Stock	17	167.49	2.8K	7,515	D	↗
2025-07-21	CARTER ROBERT B	Director	L-Small	A	Common Stock	7	167.51	1.2K	2,692	D	↗
2025-07-16	SAMAD SAM	Officer	F-InKind	D	Common Stock	850	169.01	143.7K	25,601	D	↗
2025-07-01	RING TIMOTHY M	Director	A-Award	A	Phantom Stock Units	236	0.00	—	16,725	D	↗
2025-07-01	Lassiter Wright III	Director	A-Award	A	Phantom Stock Units	160	0.00	—	521	D	↗
2025-05-15	RING TIMOTHY M	Director	A-Award	A	Common Stock	1,203	0.00	—	29,507	D	↗
2025-05-15	PFEIFFER GARY M	Director	A-Award	A	Common Stock	1,203	0.00	—	30,669	D	↗
2025-05-15	MORRISON DENISE M	Director	A-Award	A	Common Stock	1,203	0.00	—	10,742	D	↗
2025-05-15	MAIN TIMOTHY L	Director	A-Award	A	Common Stock	1,203	0.00	—	26,297	D	↗
2025-05-15	Lassiter Wright III	Director	A-Award	A	Common Stock	1,203	0.00	—	9,037	D	↗
2025-05-15	Gregg Vicky B	Director	A-Award	A	Common Stock	1,203	0.00	—	18,138	D	↗
2025-05-15	Doi Tracey	Director	A-Award	A	Common Stock	1,203	0.00	—	6,490	D	↗
2025-05-15	Diaz Luis	Director	A-Award	A	Common Stock	1,203	0.00	—	4,054	D	↗
2025-05-15	CARTER ROBERT B	Director	A-Award	A	Common Stock	1,203	0.00	—	2,685	D	↗
2025-05-13	DELANEY MARK E	Officer	S-Sale	D	Common Stock	874	175.31	153.2K	7,498	D	↗
2025-05-12	DELANEY MARK E	Officer	S-Sale	D	Common Stock	874	175.72	153.6K	8,372	D	↗
2025-04-21	SAMAD SAM	Officer	L-Small	A	Common Stock	74	164.42	12.2K	26,451	D	↗
2025-04-21	Plewman Patrick	Officer	L-Small	A	Common Stock	81	164.42	13.3K	21,087	D	↗
2025-04-21	KUPPUSAMY KARTHIK	Officer	L-Small	A	Common Stock	27	164.42	4.4K	10,612	D	↗
2025-04-21	Gregg Vicky B	Director	A-Award	A	Common Stock	68	164.42	11.2K	16,935	D	↗
2025-04-21	DELANEY MARK E	Officer	L-Small	A	Common Stock	25	164.42	4.1K	9,246	D	↗
2025-04-02	KUPPUSAMY KARTHIK	Officer	S-Sale	D	Common Stock	2,555	170.00	434.4K	10,575	D	↗
2025-04-02	Davis J. E.	Director / Officer	S-Sale	D	Common Stock	5,900	168.66	995.1K	134,565	D	↗
2025-04-01	RING TIMOTHY M	Director	A-Award	A	Phantom Stock Units	251	0.00	—	16,410	D	↗
2025-04-01	Lassiter Wright III	Director	A-Award	A	Phantom Stock Units	169	0.00	—	360	D	↗
2025-03-26	Plewman Patrick	Officer	F-InKind	D	Common Stock	162	166.71	27.0K	20,988	D	↗
2025-03-26	DELANEY MARK E	Officer	F-InKind	D	Common Stock	256	166.71	42.7K	9,221	D	↗
2025-03-17	PREVOZNIK MICHAEL E	Officer	S-Sale	D	Common Stock	4,643	170.00	789.3K	38,117	D	↗
2025-03-05	Doherty Catherine T.	Officer	S-Sale	D	Common Stock	5,370	174.13	935.1K	68,068	D	↗
2025-03-04	SAMAD SAM	Officer	A-Award	A	Common Stock	13,884	173.74	2.41M	34,061	D	↗
2025-03-04	Plewman Patrick	Officer	A-Award	A	Common Stock	5,674	173.74	985.8K	23,430	D	↗
2025-03-04	PREVOZNIK MICHAEL E	Officer	A-Award	A	Common Stock	8,549	173.74	1.49M	46,666	D	↗
2025-03-04	KUPPUSAMY KARTHIK	Officer	A-Award	A	Common Stock	4,434	173.74	770.4K	14,998	D	↗
2025-03-04	Doherty Catherine T.	Officer	F-InKind	D	Common Stock	5,010	173.74	870.4K	73,438	D	↗
2025-03-04	Davis J. E.	Director / Officer	A-Award	A	Common Stock	61,917	173.74	10.76M	198,470	D	↗
2025-03-04	DEPPE MICHAEL J	Officer	A-Award	A	Common Stock	1,711	173.74	297.3K	35,232	D	↗
2025-03-04	DELANEY MARK E	Officer	A-Award	A	Common Stock	5,317	173.74	923.8K	11,300	D	↗
2025-03-03	Plewman Patrick	Officer	F-InKind	D	Common Stock	106	173.74	18.4K	17,756	D	↗
2025-03-03	PREVOZNIK MICHAEL E	Officer	F-InKind	D	Common Stock	322	173.74	55.9K	38,709	D	↗
2025-03-03	KUPPUSAMY KARTHIK	Officer	F-InKind	D	Common Stock	992	173.74	172.4K	10,564	D	↗
2025-03-03	Doherty Catherine T.	Officer	F-InKind	D	Common Stock	394	173.74	68.5K	68,784	D	↗
2025-03-03	Davis J. E.	Director / Officer	F-InKind	D	Common Stock	1,662	173.74	288.8K	136,553	D	↗
2025-03-03	DEPPE MICHAEL J	Officer	F-InKind	D	Common Stock	1,692	173.74	294.0K	33,521	D	↗
2025-02-27	PREVOZNIK MICHAEL E	Officer	S-Sale	D	Common Stock	528	172.61	91.1K	39,031	D	↗
2025-02-27	Doherty Catherine T.	Officer	S-Sale	D	Common Stock	824	172.61	142.2K	69,178	D	↗
2025-02-26	SAMAD SAM	Officer	F-InKind	D	Common Stock	869	171.75	149.3K	20,177	D	↗
2025-02-26	Plewman Patrick	Officer	F-InKind	D	Common Stock	229	171.75	39.3K	17,853	D	↗
2025-02-26	PREVOZNIK MICHAEL E	Officer	F-InKind	D	Common Stock	286	171.75	49.1K	39,559	D	↗
2025-02-26	KUPPUSAMY KARTHIK	Officer	F-InKind	D	Common Stock	233	171.75	40.0K	11,546	D	↗
2025-02-26	Doherty Catherine T.	Officer	F-InKind	D	Common Stock	455	171.75	78.1K	70,002	D	↗
2025-02-26	Davis J. E.	Director / Officer	F-InKind	D	Common Stock	2,966	171.75	509.4K	138,215	D	↗
2025-02-26	DEPPE MICHAEL J	Officer	F-InKind	D	Common Stock	88	171.75	15.1K	35,212	D	↗
2025-02-26	DELANEY MARK E	Officer	F-InKind	D	Common Stock	214	171.75	36.8K	5,983	D	↗
2025-02-20	PREVOZNIK MICHAEL E	Officer	S-Sale	D	Common Stock	604	170.99	103.3K	39,845	D	↗
2025-02-20	Doherty Catherine T.	Officer	S-Sale	D	Common Stock	899	170.99	153.7K	70,457	D	↗
2025-02-19	SAMAD SAM	Officer	F-InKind	D	Common Stock	1,031	169.71	175.0K	21,046	D	↗
2025-02-19	Plewman Patrick	Officer	S-Sale	D	Common Stock	320	169.71	54.3K	18,082	D	↗
2025-02-19	PREVOZNIK MICHAEL E	Officer	F-InKind	D	Common Stock	374	169.71	63.5K	40,449	D	↗
2025-02-19	KUPPUSAMY KARTHIK	Officer	F-InKind	D	Common Stock	287	169.71	48.7K	11,779	D	↗
2025-02-19	Doherty Catherine T.	Officer	S-Sale	D	Common Stock	535	169.71	90.8K	71,356	D	↗
2025-02-19	Davis J. E.	Director / Officer	F-InKind	D	Common Stock	2,936	169.71	498.3K	141,181	D	↗
2025-02-19	DEPPE MICHAEL J	Officer	F-InKind	D	Common Stock	99	169.71	16.8K	35,300	D	↗
2025-02-19	DELANEY MARK E	Officer	F-InKind	D	Common Stock	242	169.71	41.1K	6,197	D	↗
2025-02-12	SAMAD SAM	Officer	A-Award	A	Non-Qualifed Stock Option (right to buy)	17,403	165.30	2.88M	17,403	D	↗
2025-02-12	Plewman Patrick	Officer	A-Award	A	Non-Qualifed Stock Option (right to buy)	7,833	165.30	1.29M	7,833	D	↗
2025-02-12	PREVOZNIK MICHAEL E	Officer	A-Award	A	Non-Qualifed Stock Option (right to buy)	8,991	165.30	1.49M	8,991	D	↗
2025-02-12	KUPPUSAMY KARTHIK	Officer	A-Award	A	Non-Qualifed Stock Option (right to buy)	8,702	165.30	1.44M	8,702	D	↗
2025-02-12	Doherty Catherine T.	Officer	A-Award	A	Non-Qualifed Stock Option (right to buy)	13,344	165.30	2.21M	13,344	D	↗
2025-02-12	Davis J. E.	Director / Officer	A-Award	A	Non-Qualifed Stock Option (right to buy)	69,633	165.30	11.51M	69,633	D	↗
2025-02-12	DEPPE MICHAEL J	Officer	A-Award	A	Common Stock	454	0.00	—	35,399	D	↗
2025-02-12	DELANEY MARK E	Officer	A-Award	A	Common Stock	1,815	0.00	—	6,439	D	↗
2025-02-05	Gregg Vicky B	Director	S-Sale	D	Common Stock	1,250	164.57	205.7K	16,867	D	↗
2025-02-05	DELANEY MARK E	Officer	S-Sale	D	Common Stock	403	164.30	66.2K	4,624	D	↗
2025-01-29	SAMAD SAM	Officer	L-Small	A	Common Stock	35	158.04	5.5K	17,539	D	↗
2025-01-29	Plewman Patrick	Officer	L-Small	A	Common Stock	57	158.04	9.0K	16,345	D	↗
2025-01-29	KUPPUSAMY KARTHIK	Officer	L-Small	A	Common Stock	12	158.03	1.9K	9,780	D	↗
2025-01-29	Gregg Vicky B	Director	L-Small	A	Common Stock	72	158.04	11.4K	18,117	D	↗
2025-01-29	DELANEY MARK E	Officer	L-Small	A	Common Stock	4	158.03	632.10	5,027	D	↗
2025-01-02	RING TIMOTHY M	Director	A-Award	A	Phantom Stock Units	281	0.00	—	16,081	D	↗
2025-01-02	Lassiter Wright III	Director	A-Award	A	Phantom Stock Units	190	0.00	—	190	D	↗
2024-11-29	PREVOZNIK MICHAEL E	Officer	M-Exempt	A	Common Stock	35,146	86.63	3.04M	73,624	D	↗
2024-11-27	Doherty Catherine T.	Officer	M-Exempt	A	Common Stock	33,103	103.57	3.43M	101,515	D	↗
2024-11-06	DEPPE MICHAEL J	Officer	M-Exempt	A	Common Stock	8,635	71.17	614.6K	43,576	D	↗
2024-10-28	KUPPUSAMY KARTHIK	Officer	S-Sale	D	Common Stock	1,775	156.92	278.5K	9,734	D	↗
2024-10-21	SAMAD SAM	Officer	L-Small	A	Common Stock	37	149.37	5.5K	17,504	D	↗
2024-10-21	Plewman Patrick	Officer	L-Small	A	Common Stock	60	149.37	9.0K	16,258	D	↗
2024-10-21	KUPPUSAMY KARTHIK	Officer	L-Small	A	Common Stock	21	149.37	3.1K	11,509	D	↗
2024-10-21	Gregg Vicky B	Director	L-Small	A	Common Stock	76	149.37	11.4K	18,045	D	↗
2024-10-21	DELANEY MARK E	Officer	L-Small	A	Common Stock	4	149.39	597.55	5,023	D	↗
2024-10-01	RING TIMOTHY M	Director	A-Award	A	Phantom Stock Units	275	0.00	—	15,721	D	↗
2024-09-24	GARDNER MARK A	Officer	F-InKind	D	Common Stock	120	155.70	18.7K	4,673	D	↗
2024-08-29	PREVOZNIK MICHAEL E	Officer	M-Exempt	A	Common Stock	32,551	95.80	3.12M	71,029	—	↗
2024-08-28	KUPPUSAMY KARTHIK	Officer	S-Sale	D	Common Stock	1,990	153.26	305.0K	11,459	—	↗
2024-08-14	KUPPUSAMY KARTHIK	Officer	F-InKind	D	Common Stock	74	149.46	11.1K	13,449	—	↗
2024-07-24	DELANEY MARK E	Officer	S-Sale	D	Common Stock	420	143.08	60.1K	5,019	—	↗
2024-07-22	SAMAD SAM	Officer	L-Small	A	Common Stock	21	146.97	3.1K	17,467	—	↗
2024-07-22	Plewman Patrick	Officer	L-Small	A	Common Stock	60	146.97	8.8K	16,162	—	↗
2024-07-22	KUPPUSAMY KARTHIK	Officer	L-Small	A	Common Stock	31	146.97	4.6K	13,511	—	↗
2024-07-22	Gregg Vicky B	Director	L-Small	A	Common Stock	77	146.97	11.3K	17,969	—	↗
2024-07-22	DELANEY MARK E	Officer	L-Small	A	Common Stock	6	146.98	881.90	5,439	—	↗
2024-07-16	SAMAD SAM	Officer	F-InKind	D	Common Stock	3,910	142.65	557.8K	17,446	—	↗
2024-07-01	RING TIMOTHY M	Director	A-Award	A	Phantom Stock Units	308	0.00	—	15,367	—	↗
2024-05-16	RING TIMOTHY M	Director	A-Award	A	Common Stock	1,482	0.00	—	27,798	—	↗
2024-05-16	PFEIFFER GARY M	Director	A-Award	A	Common Stock	1,482	0.00	—	28,916	—	↗
2024-05-16	MORRISON DENISE M	Director	A-Award	A	Common Stock	1,482	0.00	—	9,490	—	↗
2024-05-16	MAIN TIMOTHY L	Director	A-Award	A	Common Stock	1,482	0.00	—	25,094	—	↗
2024-05-16	Lassiter Wright III	Director	A-Award	A	Common Stock	1,482	0.00	—	7,709	—	↗
2024-05-16	Gregg Vicky B	Director	A-Award	A	Common Stock	1,482	0.00	—	17,892	—	↗
2024-05-16	Doi Tracey	Director	A-Award	A	Common Stock	1,482	0.00	—	5,183	—	↗
2024-05-16	Diaz Luis	Director	A-Award	A	Common Stock	1,482	0.00	—	2,851	—	↗

Executive team

Top executives

EBIT / Employee

29.5K

Shares Outstanding

110.70M

Executive compensation

Executive compensation (annual)

#	Year ⇅	Executive ⇅	Salary ⇅	Bonus	Stock award ⇅	Option award	Incentive	Other	Total ⇅	% Stock- based ⇅	Filing
1	2025	James E. Davis Chairman, Chief Executive Officer and President	1.25M	—	8.76M	3.00M	2.21M	279.9K	15.50M	75.90%	↗
2	2025	Sam A. Samad Executive Vice President and Chief Financial Officer	693.3K	—	2.19M	749.7K	710.4K	82.8K	4.43M	66.42%	↗
3	2025	Catherine T. Doherty Executive Vice President, Regional Businesses	643.3K	—	1.68M	574.9K	615.2K	49.9K	3.56M	63.28%	↗
4	2025	Karthik Kuppusamy Senior Vice President, Clinical Solutions	568.3K	—	1.10M	374.9K	475.5K	65.7K	2.58M	57.00%	↗
5	2025	Michael E. Prevoznik Senior Vice President and General Counsel	550.0K	—	1.13M	387.3K	438.3K	55.9K	2.56M	59.27%	↗
6	2024	James E. Davis Chairman, Chief Executive Officer and President	1.25M	—	8.24M	2.84M	1.81M	260.3K	14.40M	76.94%	↗
7	2024	Sam A. Samad Executive Vice President and Chief Financial Officer	668.3K	—	2.03M	699.9K	581.0K	91.0K	4.07M	67.06%	↗
8	2024	Catherine T. Doherty Executive Vice President, Regional Businesses	618.3K	—	1.59M	549.8K	477.8K	46.4K	3.29M	65.23%	↗
9	2024	Michael E. Prevoznik Senior Vice President and General Counsel	550.0K	—	1.09M	374.9K	371.9K	45.2K	2.43M	60.18%	↗
10	2024	Karthik Kuppusamy Senior Vice President, Clinical Solutions	543.3K	—	978.0K	337.4K	367.4K	51.7K	2.28M	57.75%	↗
11	2023	James E. Davis Chairman, Chief Executive Officer and President	1.18M	—	7.29M	2.50M	1.36M	346.7K	12.67M	77.25%	↗
12	2023	Sam A. Samad Executive Vice President and Chief Financial Officer	650.0K	—	1.97M	674.9K	451.9K	229.7K	3.98M	66.50%	↗
13	2023	Catherine T. Doherty Executive Vice President, Regional Businesses	600.0K	—	1.60M	549.8K	370.8K	34.1K	3.16M	68.19%	↗
14	2023	Michael E. Prevoznik Senior Vice President and General Counsel	542.5K	—	1.02M	349.9K	293.4K	45.4K	2.25M	60.87%	↗
15	2023	Karthik Kuppusamy Senior Vice President, Clinical Solutions	512.5K	—	875.1K	299.8K	291.0K	36.8K	2.02M	58.30%	↗
16	2022	Stephen H. Rusckowski Former Chairman, Chief Executive Officer and President	1.28M	—	8.35M	2.87M	2.86M	317.2K	15.68M	71.60%	↗
17	2022	James E. Davis Chairman, Chief Executive Officer and President	805.8K	—	8.54M	1.25M	1.08M	202.0K	11.88M	82.41%	↗
18	2022	Sam A. Samad Executive Vice President and Chief Financial Officer	300.0K	1.20M	3.33M	624.9K	725.7K	87.5K	6.27M	63.10%	↗
19	2022	Carrie Eglinton Manner Former Senior Vice President, Advanced and General Diagnostics and Clinical Solutions	270.7K	—	3.39M	499.9K	—	48.4K	4.21M	92.42%	↗
20	2022	Catherine T. Doherty Executive Vice President, Regional Businesses	594.2K	—	1.23M	424.9K	580.5K	39.2K	2.87M	57.75%	↗
21	2022	Catherine T. Doherty Senior Vice President, Regional Businesses	594.2K	—	1.23M	424.9K	580.5K	39.2K	2.87M	57.75%	↗
22	2022	Mark J. Guinan Former Executive Vice President and Chief Financial Officer	398.5K	—	835.1K	801.1K	444.9K	61.9K	2.54M	64.38%	↗
23	2022	Michael E. Prevoznik Senior Vice President and General Counsel	535.0K	—	1.02M	349.8K	487.8K	53.9K	2.44M	55.93%	↗
24	2022	Patrick Plewman Senior Vice President, Diagnostic Services Former Executive Officers	512.1K	—	728.2K	249.8K	441.3K	48.6K	1.98M	49.39%	↗
25	2021	Stephen H. Rusckowski Chairman, President and Chief Executive Officer	1.24M	—	7.63M	2.62M	2.70M	367.8K	14.56M	70.45%	↗
26	2021	Stephen H. Rusckowski Former Chairman, Chief Executive Officer and President	1.24M	—	7.63M	2.62M	2.70M	367.8K	14.56M	70.45%	↗
27	2021	Mark J. Guinan Executive Vice President and Chief Financial Officer	643.1K	—	1.57M	689.9K	839.8K	77.4K	3.82M	59.13%	↗
28	2021	Mark J. Guinan Former Executive Vice President and Chief Financial Officer	643.1K	—	1.57M	689.9K	839.8K	77.4K	3.82M	59.13%	↗
29	2021	James E. Davis Chairman, Chief Executive Officer and President	625.4K	—	1.57M	689.9K	816.7K	72.0K	3.77M	59.85%	↗
30	2021	James E. Davis Executive Vice President, General Diagnostics and CEO-Elect	625.4K	—	1.57M	689.9K	816.7K	72.0K	3.77M	59.85%	↗
31	2021	Carrie Eglinton Manner Former Senior Vice President, Advanced and General Diagnostics and Clinical Solutions	600.0K	—	1.36M	600.0K	696.5K	65.4K	3.32M	59.04%	↗
32	2021	Carrie Eglinton Manner Senior Vice President, Advanced and General Diagnostics and Clinical Solutions	600.0K	—	1.36M	600.0K	696.5K	65.4K	3.32M	59.04%	↗
33	2021	Catherine T. Doherty Senior Vice President, Regional Businesses	575.0K	—	1.09M	479.9K	625.7K	40.6K	2.81M	55.85%	↗
34	2021	Catherine T. Doherty Executive Vice President, Regional Businesses	575.0K	—	1.09M	479.9K	625.7K	40.6K	2.81M	55.85%	↗
35	2020	Stephen H. Rusckowski Former Chairman, Chief Executive Officer and President	1.11M	—	7.28M	2.50M	3.00M	194.0K	14.08M	69.45%	↗
36	2020	Stephen H. Rusckowski Chairman, President and Chief Executive Officer	1.11M	—	7.28M	2.50M	3.00M	194.0K	14.08M	69.45%	↗
37	2020	Mark J. Guinan Executive Vice President and Chief Financial Officer	591.4K	—	1.57M	690.0K	905.9K	46.6K	3.80M	59.41%	↗
38	2020	Mark J. Guinan Former Executive Vice President and Chief Financial Officer	591.4K	—	1.57M	690.0K	905.9K	46.6K	3.80M	59.41%	↗
39	2020	James E. Davis Chairman, Chief Executive Officer and President	577.2K	—	1.57M	690.0K	815.1K	42.9K	3.69M	61.16%	↗
40	2020	James E. Davis Executive Vice President, General Diagnostics	577.2K	—	1.57M	690.0K	815.1K	42.9K	3.69M	61.16%	↗
41	2020	James E. Davis Executive Vice President, General Diagnostics and CEO-Elect	577.2K	—	1.57M	690.0K	815.1K	42.9K	3.69M	61.16%	↗
42	2020	Manuel O. Mendez Former Senior Vice President and Chief Commercial Officer	572.3K	—	1.36M	600.0K	—	995.2K	3.53M	55.63%	↗
43	2020	Carrie Eglinton Manner Senior Vice President, Advanced Diagnostics	566.5K	—	1.36M	600.0K	707.5K	40.0K	3.28M	59.92%	↗
44	2020	Carrie Eglinton Manner Senior Vice President, Advanced and General Diagnostics and Clinical Solutions	566.5K	—	1.36M	600.0K	707.5K	40.0K	3.28M	59.92%	↗
45	2020	Carrie Eglinton Manner Former Senior Vice President, Advanced and General Diagnostics and Clinical Solutions	566.5K	—	1.36M	600.0K	707.5K	40.0K	3.28M	59.92%	↗
46	2019	Stephen H. Rusckowski Chairman, President and Chief Executive Officer	1.10M	—	4.35M	3.04M	1.37M	256.7K	10.12M	73.02%	↗
47	2019	Manuel O. Mendez Former Senior Vice President and Chief Commercial Officer	148.0K	800.0K	2.89M	266.6K	480.0K	—	4.58M	68.84%	↗
48	2019	Manuel O. Mendez Senior Vice President and Chief Commercial Officer	148.0K	800.0K	2.89M	266.6K	480.0K	—	4.58M	68.84%	↗
49	2019	Mark J. Guinan Executive Vice President and Chief Financial Officer	620.0K	—	1.29M	899.9K	464.6K	44.2K	3.32M	65.96%	↗
50	2019	James E. Davis Executive Vice President, General Diagnostics	590.0K	—	1.23M	859.9K	402.1K	40.8K	3.12M	66.93%	↗
51	2019	James E. Davis Executive Vice President, General Diagnostics and CEO-Elect	590.0K	—	1.23M	859.9K	402.1K	40.8K	3.12M	66.93%	↗
52	2019	Carrie Eglinton Manner Senior Vice President, Advanced and General Diagnostics and Clinical Solutions	575.0K	—	1.00M	699.9K	354.1K	47.3K	2.68M	63.54%	↗
53	2019	Carrie Eglinton Manner Senior Vice President, Advanced Diagnostics	575.0K	—	1.00M	699.9K	354.1K	47.3K	2.68M	63.54%	↗
54	2018	Stephen H. Rusckowski Chairman, President and Chief Executive Officer	1.10M	—	4.65M	3.10M	788.7K	314.6K	9.95M	77.86%	↗
55	2018	Mark J. Guinan Executive Vice President and Chief Financial Officer	613.1K	—	1.38M	919.9K	263.7K	56.5K	3.23M	71.14%	↗
56	2018	James E. Davis Executive Vice President, General Diagnostics	590.0K	—	1.32M	879.9K	225.6K	51.0K	3.07M	71.74%	↗
57	2018	Carrie Eglinton Manner Senior Vice President, Advanced Diagnostics	575.0K	—	1.05M	699.9K	206.1K	354.9K	2.89M	60.64%	↗
58	2018	Catherine T. Doherty Senior Vice President, Group Executive Clinical Franchises	575.0K	—	900.1K	599.9K	206.1K	38.1K	2.32M	64.68%	↗
59	2017	Stephen H. Rusckowski Chairman, President and Chief Executive Officer	1.10M	—	4.50M	3.00M	1.44M	304.6K	10.35M	72.48%	↗
60	2017	Mark J. Guinan Executive Vice President and Chief Financial Officer	590.0K	—	1.38M	920.0K	516.1K	54.3K	3.46M	66.47%	↗
61	2017	James E. Davis Executive Vice President, General Diagnostics	590.0K	—	1.32M	879.9K	430.1K	50.1K	3.27M	67.27%	↗
62	2017	Carrie Eglinton Manner Senior Vice President Advanced Diagnostics	577.2K	—	900.1K	599.9K	420.8K	117.5K	2.62M	57.35%	↗
63	2017	Carrie Eglinton Manner Senior Vice President, Advanced Diagnostics	577.2K	—	900.1K	599.9K	420.8K	117.5K	2.62M	57.35%	↗
64	2017	Catherine T. Doherty Senior Vice President, Group Executive Clinical Franchises	575.0K	—	900.1K	599.9K	419.2K	37.8K	2.53M	59.24%	↗
65	2016	Stephen H. Rusckowski Chairman, President and Chief Executive Officer	1.10M	—	4.50M	3.00M	1.34M	311.2K	10.25M	73.15%	↗
66	2016	Mark J. Guinan Executive Vice President and Chief Financial Officer	586.5K	—	1.26M	840.0K	495.2K	52.9K	3.23M	64.92%	↗
67	2016	James E. Davis Executive Vice President, General Diagnostics	586.5K	—	1.20M	799.9K	412.6K	54.8K	3.05M	65.49%	↗
68	2016	Catherine T. Doherty Senior Vice President, Group Executive Clinical Franchises	575.0K	—	900.1K	599.9K	404.5K	34.6K	2.51M	59.66%	↗
69	2016	Dr. Jon R. Cohen Senior Vice President, Group Executive Diagnostics Solutions	575.0K	—	900.1K	599.9K	404.5K	12.5K	2.49M	60.19%	↗
70	2015	Stephen H. Rusckowski President and Chief Executive Officer	1.13M	—	4.20M	2.80M	1.30M	282.7K	9.71M	72.06%	↗
71	2015	Stephen H. Rusckowski Chairman, President and Chief Executive Officer	1.13M	—	4.20M	2.80M	1.30M	282.7K	9.71M	72.06%	↗
72	2015	Mark J. Guinan Senior Vice President and Chief Financial Officer	590.4K	—	1.26M	839.9K	471.8K	52.9K	3.22M	65.32%	↗
73	2015	Mark J. Guinan Executive Vice President and Chief Financial Officer	590.4K	—	1.26M	839.9K	471.8K	52.9K	3.22M	65.32%	↗
74	2015	James E. Davis Executive Vice President, General Diagnostics	590.4K	—	1.14M	759.9K	393.2K	47.3K	2.93M	64.83%	↗
75	2015	James E. Davis Senior Vice President, Group Executive Regional Businesses	590.4K	—	1.14M	759.9K	393.2K	47.3K	2.93M	64.83%	↗
76	2015	Catherine T. Doherty Senior Vice President, Group Executive Clinical Franchises	587.7K	—	1.05M	699.9K	391.4K	37.0K	2.77M	63.27%	↗
77	2015	Dr. Jon R. Cohen Senior Vice President, Group Executive Diagnostics Solutions	596.8K	—	1.05M	699.9K	397.5K	12.5K	2.76M	63.48%	↗
78	2014	Stephen H. Rusckowski Chairman, President and Chief Executive Officer	1.05M	—	4.02M	2.68M	1.29M	225.3K	9.27M	72.30%	↗
79	2014	Stephen H. Rusckowski President and Chief Executive Officer	1.05M	—	4.02M	2.68M	1.29M	225.3K	9.27M	72.30%	↗
80	2014	Mark J. Guinan Executive Vice President and Chief Financial Officer	550.0K	—	1.20M	800.1K	468.3K	67.4K	3.09M	64.82%	↗
81	2014	Mark J. Guinan Senior Vice President and Chief Financial Officer	550.0K	—	1.20M	800.1K	468.3K	67.4K	3.09M	64.82%	↗
82	2014	Dr. Jon R. Cohen Senior Vice President, Group Executive Diagnostics Solutions	573.9K	—	1.05M	700.1K	380.0K	8.9K	2.71M	64.51%	↗
83	2014	Dr. Jon R. Cohen Senior Vice President and Chief Medical Officer	573.9K	—	1.05M	700.1K	380.0K	8.9K	2.71M	64.51%	↗
84	2014	Catherine T. Doherty Senior Vice President, Group Executive Clinical Franchises	534.6K	—	1.05M	700.1K	354.0K	37.1K	2.68M	65.40%	↗
85	2014	Catherine T. Doherty Senior Vice President, Clinical Franchises	534.6K	—	1.05M	700.1K	354.0K	37.1K	2.68M	65.40%	↗
86	2014	James E. Davis Executive Vice President, General Diagnostics	536.5K	—	1.05M	700.1K	355.3K	25.8K	2.67M	65.60%	↗
87	2014	James E. Davis Senior Vice President, Operations	536.5K	—	1.05M	700.1K	355.3K	25.8K	2.67M	65.60%	↗
88	2014	James E. Davis Senior Vice President, Group Executive Regional Businesses	536.5K	—	1.05M	700.1K	355.3K	25.8K	2.67M	65.60%	↗
89	2013	Stephen H. Rusckowski President and Chief Executive Officer	1.05M	—	4.58M	2.12M	134.3K	288.9K	8.17M	81.97%	↗
90	2013	Robert A. Hagemann Former Senior Vice President and Chief Financial Officer	355.5K	—	1.57M	729.3K	—	2.94M	5.60M	41.08%	↗
91	2013	Mark J. Guinan Senior Vice President and Chief Financial Officer	222.1K	250.0K	2.70M	799.6K	19.7K	73.1K	4.06M	86.10%	↗
92	2013	Dr. Jon R. Cohen Senior Vice President, Group Executive Diagnostics Solutions	573.9K	—	1.20M	554.9K	39.5K	46.9K	2.41M	72.60%	↗
93	2013	Dr. Jon R. Cohen Senior Vice President and Chief Medical Officer	573.9K	—	1.20M	554.9K	39.5K	46.9K	2.41M	72.60%	↗
94	2013	John B. Haydon Senior Vice President, Operations	565.0K	—	1.20M	554.9K	41.7K	20.0K	2.38M	73.63%	↗
95	2013	Catherine T. Doherty Senior Vice President, Clinical Franchises	520.0K	—	1.20M	554.9K	35.8K	47.3K	2.35M	74.37%	↗
96	2013	Catherine T. Doherty Senior Vice President, Clinical Franchises Former Executive Officer	520.0K	—	1.20M	554.9K	35.8K	47.3K	2.35M	74.37%	↗
97	2013	Catherine T. Doherty Senior Vice President, Group Executive Clinical Franchises	520.0K	—	1.20M	554.9K	35.8K	47.3K	2.35M	74.37%	↗
98	2012	Stephen H. Rusckowski President and Chief Executive Officer	682.5K	500.0K	7.27M	2.68M	1.37M	479.4K	12.97M	76.67%	↗
99	2012	Dr. Surya N. Mohapatra Former Chairman, President and Chief Executive Officer	501.0K	8.00	—	—	—	6.76M	7.87M	0.00%	↗
100	2012	Dr. Joan E. Miller Former Senior Vice President, Pathology and Neurology	516.0K	—	1.23M	698.4K	—	2.10M	4.54M	42.38%	↗
101	2012	Robert A. Hagemann Former Senior Vice President and Chief Financial Officer	571.2K	—	1.73M	984.1K	364.5K	73.1K	3.72M	72.89%	↗
102	2012	Robert A. Hagemann Senior Vice President and Chief Financial Officer	571.2K	—	1.73M	984.1K	364.5K	73.1K	3.72M	72.89%	↗
103	2012	Dr. Jon R. Cohen Senior Vice President and Chief Medical Officer	573.9K	—	1.14M	651.4K	379.8K	48.0K	2.80M	64.19%	↗
104	2012	Catherine T. Doherty Senior Vice President, Clinical Franchises Former Executive Officer	520.0K	—	1.23M	698.4K	204.0K	43.3K	2.69M	71.50%	↗
105	2012	Catherine T. Doherty Senior Vice President, Clinical Franchises	520.0K	—	1.23M	698.4K	204.0K	43.3K	2.69M	71.50%	↗
106	2012	Michael E. Prevoznik, Senior Vice President and General Counsel Former Executive Officers	492.1K	—	858.0K	488.6K	202.2K	49.5K	2.09M	64.42%	↗
107	2011	Surya N. Mohapatra Chairman, President and Chief Executive Officer	1.23M	—	5.19M	2.57M	1.61M	2.17M	12.78M	60.76%	↗
108	2011	Dr. Surya N. Mohapatra Former Chairman, President and Chief Executive Officer	1.23M	—	5.19M	2.57M	1.61M	2.17M	12.78M	60.76%	↗
109	2011	Kathy Ordoñez Senior Vice President, Discovery and Development	314.6K	—	1.60M	—	238.2K	2.31M	4.47M	35.89%	↗
110	2011	Robert A. Hagemann Former Senior Vice President and Chief Financial Officer	557.2K	—	2.15M	1.06M	438.3K	66.8K	4.27M	75.14%	↗
111	2011	Robert A. Hagemann Senior Vice President and Chief Financial Officer	557.2K	—	2.15M	1.06M	438.3K	66.8K	4.27M	75.14%	↗
112	2011	Dr. Jon R. Cohen Senior Vice President and Chief Medical Officer	563.8K	—	1.39M	689.7K	407.0K	39.5K	3.09M	67.34%	↗
113	2011	Jon R. Cohen Senior Vice President, Hospital and Chief Medical Officer	563.8K	—	1.39M	689.7K	407.0K	39.5K	3.09M	67.34%	↗
114	2011	Joan E. Miller Senior Vice President Pathology and Neurology	501.1K	—	1.39M	689.7K	322.8K	43.9K	2.95M	70.59%	↗
115	2011	Dr. Joan E. Miller Former Senior Vice President, Pathology and Neurology	501.1K	—	1.39M	689.7K	322.8K	43.9K	2.95M	70.59%	↗
116	2010	Dr. Surya N. Mohapatra Former Chairman, President and Chief Executive Officer	1.23M	—	5.33M	2.64M	1.20M	1.94M	12.34M	64.51%	↗
117	2010	Surya N. Mohapatra Chairman, President and Chief Executive Officer	1.23M	—	5.33M	2.64M	1.20M	1.94M	12.34M	64.51%	↗
118	2010	Robert A. Hagemann Senior Vice President and Chief Financial Officer	557.2K	—	2.21M	1.10M	327.2K	85.3K	4.28M	77.34%	↗
119	2010	Dr. Jon R. Cohen Senior Vice President and Chief Medical Officer	563.8K	—	1.44M	710.7K	239.1K	25.0K	2.97M	72.17%	↗
120	2010	Jon R. Cohen Senior Vice President and Chief Medical Officer	563.8K	—	1.44M	710.7K	239.1K	25.0K	2.97M	72.17%	↗
121	2010	Jon R. Cohen Senior Vice President, Hospital and Chief Medical Officer	563.8K	—	1.44M	710.7K	239.1K	25.0K	2.97M	72.17%	↗
122	2010	Joan E. Miller Senior Vice President Hospital and Pathology Services	501.1K	—	1.44M	710.7K	231.2K	50.5K	2.93M	73.28%	↗
123	2010	Dr. Joan E. Miller Former Senior Vice President, Pathology and Neurology	501.1K	—	1.44M	710.7K	231.2K	50.5K	2.93M	73.28%	↗
124	2010	Joan E. Miller Senior Vice President Pathology and Neurology	501.1K	—	1.44M	710.7K	231.2K	50.5K	2.93M	73.28%	↗
125	2010	Wayne R. Simmons Vice President Operations	445.0K	100.0K	1.08M	533.0K	157.9K	73.7K	2.39M	67.46%	↗
126	2009	Surya N. Mohapatra Chairman, President and Chief Executive Officer	1.20M	—	4.90M	2.35M	2.35M	1.68M	12.47M	58.09%	↗
127	2009	Robert A. Hagemann Senior Vice President and Chief Financial Officer	541.0K	—	2.04M	975.8K	634.9K	65.1K	4.25M	70.83%	↗
128	2009	Jon R. Cohen Senior Vice President and Chief Medical Officer	412.5K	—	1.34M	609.2K	349.6K	—	2.71M	71.88%	↗
129	2009	Jon R. Cohen Senior Vice President, Hospital and Chief Medical Officer	412.5K	—	1.34M	609.2K	349.6K	—	2.71M	71.88%	↗
130	2009	Joan E. Miller Senior Vice President Pathology and Neurology	464.1K	—	1.21M	580.2K	339.8K	38.0K	2.63M	68.03%	↗
131	2009	Joan E. Miller Senior Vice President Hospital and Pathology Services	464.1K	—	1.21M	580.2K	339.8K	38.0K	2.63M	68.03%	↗
132	2009	Michael E. Prevoznik Senior Vice President and General Counsel	466.6K	—	991.0K	474.7K	395.5K	56.5K	2.38M	61.48%	↗
133	2009	Wayne R. Simmons Vice President Operations	423.8K	—	991.0K	474.7K	380.9K	44.7K	2.32M	63.31%	↗
134	2008	Surya N. Mohapatra Chairman, President and Chief Executive Officer	1.14M	—	4.35M	—	1.92M	109.2K	11.96M	36.33%	↗
135	2008	Surya N. Mohapatra Chairman, President and Chief Executive Officer	1.14M	—	4.54M	1.98M	1.92M	1.74M	11.32M	57.61%	↗
136	2008	Robert A. Hagemann Senior Vice President and Chief Financial	517.7K	—	1.78M	—	520.2K	71.3K	4.12M	43.18%	↗
137	2008	Robert A. Hagemann Senior Vice President and Chief Financial Officer	517.7K	—	1.89M	989.3K	520.2K	71.3K	3.99M	72.19%	↗
138	2008	Joan E. Miller Senior Vice President Hospital and Pathology Services	439.9K	—	1.12M	703.9K	328.2K	30.8K	2.63M	69.58%	↗
139	2008	Michael E. Prevoznik Senior Vice President and General Counsel	448.6K	—	919.2K	627.8K	325.6K	53.3K	2.37M	65.15%	↗
140	2008	Michael E. Prevoznik Senior Vice President and General Counsel	448.6K	—	861.3K	—	325.6K	53.3K	2.36M	36.48%	↗
141	2008	Joan E. Miller Senior Vice President	439.9K	—	823.8K	—	328.2K	30.8K	2.35M	35.00%	↗
142	2008	Wayne R. Simmons Vice President Operations	403.6K	—	898.8K	420.4K	320.4K	186.1K	2.23M	59.17%	↗
143	2007	Surya N. Mohapatra Chairman, President and Chief Executive Officer	1.09M	—	2.96M	4.28M	1.67M	1.21M	11.21M	64.60%	↗
144	2007	Surya N. Mohapatra Chairman, President and Chief Executive Officer	1.09M	—	758.0K	—	1.67M	116.8K	8.95M	8.47%	↗
145	2007	Robert A. Hagemann Senior Vice President and Chief Financial Officer	495.4K	—	1.18M	1.71M	453.2K	69.0K	3.91M	74.00%	↗
146	2007	Robert A. Hagemann Senior Vice President and Chief Financial	495.4K	—	303.1K	—	453.2K	69.0K	3.04M	9.96%	↗
147	2007	Robert A. Hagemann Senior Vice President and Chief Financial Officer	495.4K	—	303.1K	—	453.2K	69.0K	3.04M	9.96%	↗
148	2007	Robert E. Peters Vice President Sales and Marketing	367.9K	—	543.8K	—	245.6K	41.5K	2.37M	22.93%	↗
149	2007	Michael E. Prevoznik Senior Vice President and General Counsel	429.3K	—	571.2K	826.3K	283.6K	57.2K	2.17M	64.47%	↗
150	2007	Joan E. Miller Senior Vice President Hospital and Pathology Services	394.7K	—	595.9K	856.0K	265.8K	31.0K	2.14M	67.74%	↗
151	2007	Michael E. Prevoznik Senior Vice President and General Counsel	429.3K	—	146.5K	—	283.6K	57.2K	1.76M	8.34%	↗
152	2007	Joan E. Miller Senior Vice President	394.7K	—	140.1K	—	265.8K	31.0K	1.43M	9.83%	↗
153	2007	Joan E. Miller Senior Vice President	394.7K	—	140.1K	—	265.8K	31.0K	1.43M	9.83%	↗
154	2006	Surya N. Mohapatra Chairman, President and Chief Executive Officer	1.02M	100.0K	605.5K	—	1.95M	172.7K	9.30M	6.51%	↗
155	2006	Surya N. Mohapatra Chairman, President & Chief Executive Officer	—	—	6.68M	—	—	—	6.68M	100.00%	↗
156	2006	Robert A. Hagemann Senior Vice President and Chief Financial	463.0K	—	247.8K	—	643.2K	47.7K	3.24M	7.66%	↗
157	2006	Robert A. Hagemann Senior Vice President and Chief Financial Officer	463.0K	—	247.8K	—	643.2K	47.7K	3.24M	7.66%	↗
158	2006	Robert A. Hagemann Senior Vice President and Chief Financial Officer	—	—	2.34M	—	—	—	2.34M	100.00%	↗
159	2006	Michael E. Prevoznik Senior Vice President and General Counsel	401.2K	—	119.3K	—	386.9K	43.5K	1.87M	6.39%	↗
160	2006	David M. Zewe Senior Vice President, Diagnostic Testing Operations	—	—	1.59M	—	—	—	1.59M	100.00%	↗
161	2006	Robert E. Peters Vice President Sales and Marketing	355.4K	—	109.2K	—	335.8K	32.1K	1.59M	6.86%	↗
162	2006	Michael E. Prevoznik Senior Vice President and General Counsel	—	—	1.31M	—	—	—	1.31M	100.00%	↗
163	2006	Robert E. Peters Vice President Sales & Marketing	—	—	1.17M	—	—	—	1.17M	100.00%	↗
164	2005	Surya N. Mohapatra Chairman, President and Chief Executive Officer	965.0K	954.2K	—	257.6K	—	245.1K	2.42M	10.63%	↗
165	2005	Robert A. Hagemann Senior Vice President and Chief Financial Officer	436.8K	287.9K	—	109.3K	—	55.9K	890.0K	12.28%	↗
166	2005	David M. Zewe Senior Vice President, Diagnostic Testing Operations	462.9K	228.9K	—	53.3K	—	42.9K	788.0K	6.77%	↗
167	2005	Michael E. Prevoznik Senior Vice President and General Counsel	382.1K	188.9K	—	53.6K	—	45.4K	670.0K	7.99%	↗
168	2005	Robert E. Peters Vice President Sales and Marketing	338.5K	167.4K	—	44.0K	—	28.9K	578.7K	7.60%	↗
169	2004	Kenneth W. Freeman Former Chief Executive Officer	1.17M	2.07M	—	—	—	1.69M	4.92M	0.00%	↗
170	2004	Surya N. Mohapatra Chairman, President and Chief Executive Officer	900.2K	1.16M	—	346.3K	—	152.7K	2.56M	13.51%	↗
171	2004	Surya N. Mohapatra Chairman, President & Chief Executive Officer	900.2K	1.16M	—	173.1K	—	152.7K	2.39M	7.25%	↗
172	2004	Robert A. Hagemann Senior Vice President and Chief Financial Officer	431.5K	368.7K	—	147.2K	—	45.5K	992.9K	14.83%	↗
173	2004	David M. Zewe Senior Vice President, Diagnostic Testing Operations	448.7K	294.8K	—	86.4K	—	41.4K	871.3K	9.91%	↗
174	2004	Michael E. Prevoznik Senior Vice President and General Counsel	374.0K	239.7K	—	81.1K	—	40.8K	735.6K	11.03%	↗
175	2004	Gerald C. Marrone Senior Vice President Administration	154.6K	71.7K	—	25.3K	—	25.9K	277.5K	9.11%	↗
176	2003	Kenneth W. Freeman Former Chief Executive Officer	1.09M	1.24M	4.89M	700.0K	—	82.9K	8.01M	69.80%	↗
177	2003	Surya N. Mohapatra Chairman, President and Chief Executive Officer	597.8K	586.6K	—	369.2K	—	134.1K	1.69M	21.87%	↗
178	2003	Surya N. Mohapatra Chairman, President & Chief Executive Officer	597.8K	586.6K	—	184.6K	—	134.1K	1.50M	12.28%	↗
179	2003	Robert A. Hagemann Senior Vice President and Chief Financial Officer	379.6K	292.2K	—	180.8K	—	28.9K	881.4K	20.51%	↗
180	2003	David M. Zewe Senior Vice President, Diagnostic Testing Operations	415.6K	238.0K	—	156.0K	—	30.1K	839.7K	18.58%	↗
181	2003	Gerald C. Marrone Senior Vice President Administration	357.7K	174.7K	—	71.6K	—	152.0K	756.0K	9.47%	↗
182	2003	Michael E. Prevoznik Senior Vice President and General Counsel	320.7K	163.6K	—	72.0K	—	112.9K	669.1K	10.76%	↗
183	2002	Kenneth W. Freeman Former Chief Executive Officer	785.2K	1.36M	—	200.0K	—	330.2K	2.67M	7.49%	↗
184	2002	Surya N. Mohapatra Chairman, President & Chief Executive Officer	520.0K	513.3K	—	81.6K	—	128.8K	1.24M	6.56%	↗
185	2002	Gerald C. Marrone Senior Vice President Administration	345.8K	256.0K	—	31.5K	—	152.4K	785.7K	4.01%	↗
186	2002	David M. Zewe Senior Vice President, Diagnostic Testing Operations	375.0K	277.7K	—	38.0K	—	27.1K	717.7K	5.29%	↗
187	2002	Robert A. Hagemann Senior Vice President and Chief Financial Officer	312.0K	289.1K	—	36.5K	—	24.6K	662.2K	5.51%	↗
188	2002	Michael E. Prevoznik Senior Vice President and General Counsel	280.8K	220.6K	—	36.1K	—	106.8K	644.3K	5.60%	↗

CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)

Filing date	Form type	Filing
2026-04-06	DEFA14A	↗
2026-04-06	DEF 14A	↗

Recent SEC filings

Filing date	Form type	Filing
2026-05-21	8-K	↗
2026-05-21	4	↗
2026-05-21	4	↗
2026-05-21	4	↗
2026-05-21	4	↗
2026-05-21	4	↗
2026-05-21	4	↗
2026-05-21	4	↗
2026-05-21	4	↗
2026-05-21	4	↗

Executive team

Name	Title	Compensation	Gender
James E. Davis	Chairman, Chief Executive Officer & President	4M	male
Sam A. Samad	Executive Vice President & Chief Financial Officer	1M	male
Catherine T. Doherty	Executive Vice President of Regional Businesses	1M	female
Karthik Kuppusamy	Senior Vice President of Clinical Solutions	1M	male
Michael E. Prevoznik	Senior Vice President & General Counsel	1M	male
Kristin Lee Wallace	Senior Vice President & Chief Compliance Officer	—	female
Garry Clark	Senior Vice President and Chief Marketing & Communications Officer	—	male
Michael J. Deppe	Senior Vice President, Corporate Controller & Chief Accounting Officer	—	male
Murali Balakumar	Senior Vice President and Chief Information & Digital Officer	—	male
Dan Haemmerle	Interim VP of Investor Relations & VP Finance	—	—

ESG Rating

MEDICAL - DIAGNOSTICS & RESEARCH

Rank: 23 out of 66

2013

E (Environmental)

63.3 / 61.3

Company / Sector avg.

S (Social)

56.2 / 65.4

Company / Sector avg.

G (Governance)

63.2 / 64.9

Company / Sector avg.

ESG Total

60.9 / 63.8

Company / Sector avg.

ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH

Benchmark vs Sector

Political Trading Activity (25M)

Senate Trading Activity

Transaction Date	Disclosed	Senator	State	Owner	Type	Amount	Link
2024-01-03	2024-02-14	Tommy Tuberville	AL	Joint	Sale (Partial)	$15,001 - $50,000	↗
2023-12-11	2024-01-03	Thomas R. Carper	DE	Spouse	Sale (Partial)	$1,001 - $15,000	↗
2021-03-29	2021-07-23	Tommy Tuberville	AL	Joint	Purchase	$1,001 - $15,000	↗
2020-04-02	2020-05-04	Thomas R. Carper	DE	Spouse	Purchase	$1,001 - $15,000	↗

House Trading Activity

Transaction Date	Disclosed	Representative	District	Owner	Type	Amount	Link
2025-11-03	2025-12-12	Julie Johnson	TX32	Joint	Sale	$1,001 - $15,000	↗
2025-07-24	2026-01-13	Julia Letlow	LA05	—	Sale (Full)	$1,001 - $15,000	↗
2025-04-28	2026-01-13	Julia Letlow	LA05	—	Purchase	$1,001 - $15,000	↗
2025-03-10	2025-04-11	Carol Devine Miller	WV01	—	Sale (Full)	$1,001 - $15,000	↗
2025-01-24	2025-02-12	Gilbert Cisneros	CA31	—	Sale	$1,001 - $15,000	↗
2024-11-15	2024-12-06	Ro Khanna	CA17	—	Purchase	$1,001 - $15,000	↗
2024-04-04	2024-05-04	Earl Blumenauer	OR03	Spouse	Sale (Full)	$1,001 - $15,000	↗
2024-02-13	2024-03-06	Ro Khanna	CA17	Spouse	Sale	$1,001 - $15,000	↗
2023-10-31	2023-11-08	Ro Khanna	CA17	Spouse	Purchase	$1,001 - $15,000	↗
2023-09-06	2023-10-06	Ro Khanna	CA17	Spouse	Sale	$1,001 - $15,000	↗
2023-06-29	2023-07-11	Ro Khanna	CA17	Spouse	Purchase	$1,001 - $15,000	↗
2022-11-14	2022-12-13	Carol Devine Miller	WV03	—	Purchase	$1,001 - $15,000	↗
2022-08-03	2022-09-14	Kathy Manning	NC06	Joint	Sale (Full)	$1,001 - $15,000	↗
2022-07-20	2022-08-10	Kathy Manning	NC06	Joint	Purchase	$1,001 - $15,000	↗
2022-03-31	2022-04-18	Michael McCaul	TX10	Spouse	Sale	$50,001 - $100,000	↗
2022-03-31	2022-04-18	Michael McCaul	TX10	—	Sale	$100,001 - $250,000	↗
2022-03-14	2022-04-01	Earl Blumenauer	OR03	Self	Sale (Full)	$1,001 - $15,000	↗
2022-02-24	2022-04-01	Earl Blumenauer	OR03	Self	Purchase	$1,001 - $15,000	↗
2022-02-17	2022-03-08	Ro Khanna	CA17	Spouse	Sale	$1,001 - $15,000	↗
2022-01-28	2022-02-23	Michael McCaul	TX10	—	Sale	$1,001 - $15,000	↗

Market share among peers

Peer comparison — filtered group (TTM)

Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Quest Diagnostics Incorporated (DGX)

Index membership

Revenue flow

Revenue by geography

Revenue by segment

Revenue composition

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Owner Earnings

Ownership Overview

Institutional Activity (13F)

Insider Activity

Executive team

Executive compensation

Proxy statements

Recent SEC filings

Executive team

Community Opinion for DGX

Short-term intention

Target Price Distribution

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Quest Diagnostics Incorporated (DGX)

Index membership

Revenue flow

Revenue by geography

Revenue by segment

Revenue composition

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Owner Earnings

Ownership Overview

Institutional Activity (13F)

Insider Activity

Executive team

Executive compensation

Proxy statements

Recent SEC filings

Executive team

Community Opinion for DGX

Short-term intention

Target Price Distribution

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies